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ZUSAMMENFASSUNG 
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Ziel der hier vorliegenden Arbeit war es, den funktionellen Beitrag von Mastzellen bei 
der Arteriogenese, dem Wachstum prä-existierender arteriolärer Verbindungen zu 
natürlichen Bypässen, zu untersuchen. Hierzu wurde das Mausmodell der peripheren 
Arteriogenese verwendet, bei der durch Ligatur der Femoralarterie das Wachstum 
von Kollateralarterien induziert wird. Die Ergebnisse zeigten, dass Mastzellen nur im 
perivaskulären Raum von wachsenden Arteriolen aktiviert werden und degranulieren, 
während dies weder im distal davon gelegenen Unterschenkel, noch bei 
Scheinoperation beobachtet wurde.  
Laser-Doppler-Perfusionsmessungen belegten, dass sowohl durch die Applikation 
von C48/80, von SCF, als auch von Diprotin A, welche zur Degranulation, zur 
Reifung, beziehungsweise zur Rekrutierung von Mastzellen führten, die 
Arteriogenese gesteigert werden kann. Bei kombinierter Applikation von C48/80 und 
Diprotin A wurden additive Effekte beobachtet. Die Applikation von Cromolyn 
hingegen, welches die Degranulation von Mastzellen blockiert, reduzierte den 
Prozess der Arteriogenese selbst wenn gleichzeitig Diprotin A verabreicht wurde. 
Diese Ergebnisse belegen erstmals, dass Mastzellen eine wesentliche Funktion bei 
der Arteriogenese übernehmen. Diese Funktion wurde genauer charakterisiert. Es 
zeigte sich dass Mastzellen sowohl (a) die vaskuläre Remodellierung über 
Aktivierung von Matrixmetalloproteinasen, (b) die Rekrutierung von Leukozyten über 
eine vermehrte Bioverfügbarkeit von MCP-1 und TNF-α, als auch (c) die Proliferation 
von vaskulären Zellen, vermutlich über die Freisetzung von Wachstumsfaktoren, 
fördern und somit wesentlich zum Prozess der Arteriogenese beitragen.  
Der Verschluss einer Arterie hat unweigerlich zur Folge, dass das distal davon 
gelegene Gewebe aufgrund der Minderperfusion geschädigt wird, während dies 
durch effizientes Wachstum von natürlichen Bypässen verhindert oder zumindest 
verringert werden kann. Tatsächlich zeigen die hier erhobenen Daten, dass durch die 
iv 
 
kombinierte Applikation von C48/80 und Diprotin A die Gewebefibrose im 
Unterschenkel der behandelten Tiere auf ein Minimum reduziert werden konnte, was 
mit einer signifikant reduzierten Kapillarsprossung und Infiltration von Leukozyten 
verbunden war. 
Untersuchungen zum Auslöser der Degranulation von Mastzellen nach 
Gefäßverschluss zeigten, dass es sich hierbei um eine konzertierte Aktion handelt. 
Im Wesentlich sind hierfür reaktive Sauerstoffspezies verantwortlich, welche von der 
Neutrophilen NADPH Oxidase 2  nach Plättchen-GPIbα vermittelte Aktivierung und 
uPA abhängige Extravasation von Neutrophilen, gebildet werden. 
Zusammenfassend zeigen die Ergebnisse dieser Arbeit erstmals, dass Mastzellen 
eine essentielle Rolle bei der Arteriogenese spielen und dass durch ihre aktive 
Rekrutierung und Degranulation der Prozess der Arteriogenese so effizient gesteigert 
werden kann, dass hierdurch Gewebeschäden, welche sich in Minderperfusion 
bedingen, fast vollständig verhindert werden können. 
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1. INTRODUCTION 
1.0. Importance of arteriogenesis in cardiovascular diseases 
Cardiovascular diseases are the leading cause of death worldwide. The spread of 
western life style will increase the cardiovascular disease prevalence in developing 
countries and most significantly at younger population. An estimated 17.3 million 
people died from cardiovascular diseases in 2008, representing 30% of all global 
deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease 
and 6.2 million were due to stroke, all of these were the result of coronary or cerebral 
artery occlusion respectively (WHO, September 2011). Peripheral artery disease 
affects a large segment of the adult population, with an age-adjusted prevalence 
between 4% and 15%, affecting more than 5 million adults in the United States 
(Kasapis and Gurm, 2009). Atherosclerosis (narrowing of arterial lumen due to 
accumulation of fatty substances and plaque formation) remains to be the main 
cause of chronic peripheral arterial occlusive diseases. Embolism, thrombosis and 
trauma are acute causes of arterial occlusion. The risk of formation and progression 
of artherosclerosis, and hence of arterial occlusion is much higher in patients with 
multilevel arterial involvement, such as diabetes mellitus, chronic renal insufficiency, 
and heavy smoking (Cox et al., 1993).  
Therapeutic options to treat occlusive arterial diseases include surgical 
revascularization techniques such as percutaneous transluminal angioplasty and 
bypass surgery. These techniques have been developed over the last decades and 
can now be performed with low morbidity and mortality in patients with chronic artery 
diseases. Despite of these surgical options to treat arterial stenosis, 25–30% of the 
patients with coronary artery disease cannot be revascularised by percutaneous 
coronary intervention or coronary artery bypass grafting. Therefore, therapeutic 
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promotion of the growth of pre-existing collateral arteries (i.e. arteriogenesis) is a 
valuable treatment strategy in those patients (Seiler, 2003, Hunt, 2006). 
Arteriogenesis provides alternate routes for blood flow bypassing occluded arteries 
with the result of preventing or reducing ischemic injuries in downstream tissues 
(Schaper et al., 1976).  
 
1.1. Vascular adaptations in arteriogenesis  
Chronic changes in blood flow e.g. due to arterial occlusion results in vascular 
adaptation. This adaptation includes both arteriogenesis and angiogenesis (see figure 
1). Collateral arteries are present in almost all organs. During arteriogenesis, these 
collaterals become larger in diameter and can reach up to 25 times of their original 
size (Scholz et al., 2001). Enlarged collateral arteries can efficiently supply blood flow 
with the result that tissue necrosis is prevented or limited (Scholz et al., 2002). 
Therefore, arteriogenesis can also prevent angiogenesis by restoring blood flow to the 
ischemic tissue (Deindl et al., 2001). Angiogenesis is the sprouting of capillaries from 
pre-existing vessels (Carmeliet, 2000) in response to hypoxia in the downstream 
tissue. In contrast to angiogenesis, ischemia is not a direct driving force in 
arteriogenesis (Deindl et al., 2001).  
Arteriogenesis involves enlargement of small pre-existing arteriole into a 
conductance artery that substitute the diseased large occluded artery. The process 
includes proliferation of endothelial and smooth muscle cells and reorganization of 
extracellular matrix followed by vessel maturation and stabilization (Schaper et al., 
1971). Collateral arteries are present essentially in every tissue/organ of the body but 
the number and size of these anastomosis varies greatly between tissues as well as 
between species (Helisch and Schaper, 2003, Helisch et al., 2006). A well known 
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model for the study of arteriogenesis and angiogenesis is the experimental occlusion 
of the femoral artery in the mouse hind limb. In response to femoral artery occlusion 
collateral arteries enlarge (arteriogenesis) due to shear stress in the upper leg and 
capillaries sprout (angiogenesis) due to ischemia in the lower leg (figure 1). 
 
 
                        
 
 
                                 
  
Collateral arterioles 
       (m.adductors) 
Capillaries 
(m.gastrocnemius) 
 a.femoralis 
a.profunda 
a.genu descendens 
A. Before occlusion 
B. After occlusion 
Arteriogenesis 
Angiogenesis 
Femoral ligation 
Redirection of 
blood flow 
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Figure 1. Murine hind limb model of collateral artery growth.  
A: Sketch diagram shows the hind limb vascular blood flow through the femoral 
artery to downstream tissues.  Minimum amount of blood is passing though the 
a.profunda to the deep interconnecting arterioles in the adductor muscles. 
B: Femoral artery occlusion leads to redirection of blood flow through interconnecting 
arterioles back to the distal part of femoral artery. This phenomenon is associated 
with the development of collateral arteries (arteriogenesis) and the formation of new 
capillaries in the gastrocnemius muscle (angiogenesis).  
 
 
1.2.  Mechanisms of Arteriogenesis 
Arteriogenesis is triggered after arterial occlusion by fluid shear stress in the vessel 
wall of collateral arteries (Resnick et al., 2003). Following increased blood flow in 
collateral arteries, their endothelial cells become activated, which is seen first as cell 
swelling, caused by loss of osmotic control (Schaper et al., 1976, Chalothorn and 
Faber, 2010). This mechanical force will activate transcriptional factors such as egr-
1, which then up-regulates monocyte chemoattractant molecules (MCP-1) and 
intracellular adhesion molecules (ICAM) -1 in the collateral endothelium (Ito et al., 
1997, Hoefer et al., 2004, Pagel et al., 2012). MCP-1 recruits circulating monocytes, 
which adhere to the endothelium and finally extravasate to the perivascular space 
(Heil et al., 2002). Perivascular inflammatory cells, consisting mainly of monocytes, in 
the growing collaterals secrete growth factors and proteases necessary for 
endothelial and smooth muscle cell proliferation as well as vascular remodelling 
(Arras et al., 1998) (figure 2). Collateral arteries enlarge and remodel outwardly, 
which results in an increase in the luminal diameter (Scholz et al., 2000). As the 
luminal diameter increases, the fluid shear stress decreases and the process of 
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arteriogenesis terminates. If collateral arteries have developed adequately, distal 
perfusion will be restored.  
 
Figure 2: Mechanism of arteriogenesis 
The endothelium senses increased fluid shear stress via its surface stress receptors 
such as integrins. This increased shear stress activates the endothelium, which there 
upon expresses adhesion molecules i.e. ICAM-1, to which circulating monocytes bind 
via their Mac-1 receptor. Monocytes extravasate into perivascular tissue, differentiate 
to macrophages and finally secrete growth factors (such as FGF-2) and cytokines 
(e.g. MCP-1) that attract further monocytes and stimulate proliferation of smooth 
muscle cells and endothelial cells. 
(Schirmer et al., 2009) 
 
Fluid shear stress triggers after arterial occlusion a cascade of signals, which 
mediate arteriogenesis. A number of cell types such as monocytes/ macrophages, T-
cell lymphocytes, mast cells and stem cells have been suggested to play a role in this 
process (Schaper et al., 1976, Heil et al., 2004, van Weel et al., 2007). However, the 
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sequence of events leading from initial shear stress to remodelling of arterial 
collaterals and to an increase in reperfusion is so far only poorly understood.  
                                                 
1.3. The role of leukocytes in arteriogenesis 
1.3.1 Monocytes and macrophages  
Monocytes and macrophages were the first bone marrow derived cells shown to play 
a role in arteriogenesis (Schaper et al., 1976). Monocytes facilitate arteriogenesis 
and their suppression delays arteriogenesis significantly (Schaper and Scholz, 2003). 
The upregulation of chemokine MCP-1 on the endothelium during arteriogenesis 
attracts monocytes via integrin receptor Mac-1. The attracted monocytes finally 
adhere to the endothelium and extravasate to the perivascular space (Schaper et al., 
1976). In the vicinity of collateral arteries monocytes mature to become 
macrophages. (Arras et al., 1998, Scholz et al., 2000, Stabile et al., 2006). 
Macrophages release proteases like matrix metalloproteinases (MMP)-2 and MMP-9, 
which digest matrix and internal elastic lamina, relevant for outward remodelling of 
the collateral vessel (Tyagi et al., 1996, Haas et al., 2007, Kovanen, 2007). 
Macrophages also serve as important sources for cytokines like tumor necrosis factor 
(TNF)-α, which has been shown to enhance arteriogenesis (Hoefer et al., 2002). 
Furthermore macrophages release growth factors including fibroblast growth factor 
(FGF-2), and transforming growth factor (TGF)-ß which induce endothelial and 
smooth muscle cell proliferation (Arras et al., 1998, Heil et al., 2002, Deindl et al., 
2003). In addition, enhancing chemoattraction of monocytes to the region of collateral 
artery growth leads to enhanced arteriogenesis and significant improvement of limb 
perfusion, whereas lack of circulating monocytes impair arteriogenesis and limb 
perfusion (Heil et al., 2002).  
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1.3.2. T-cell lymphocytes 
T-lymphocytes have been shown to promote arteriogenesis (Stabile et al., 2003). In 
this study, a reduced number of macrophage and an impaired perfusion recovery by 
25% were shown in CD4-/- mice after femoral artery ligation. Additionally, CD4+ T 
cells depleted mice exhibited a significantly impaired blood flow restoration (van Weel 
et al., 2007). In another study CD8-/- mice exhibited an attenuated blood flow recovery 
in comparison to controls, and exogenous transfusion of CD8+ T cells in these mice 
improved blood flow recovery (Stabile et al., 2006). However, another study that 
investigated the role of leukocyte subpopulations (T-lymphocytes and granulocytes) 
resulted in controversial findings, since chemoattractants specific for T-lymphocytes 
and granulocytes were insufficient to stimulate arteriogenesis. Only the monocyte 
chemoattractant factor, which recruits monocytes was shown to promote 
arteriogenesis (Hoefer et al., 2005). 
 
1.3.3. Mast cell 
1.3.3.1. The origin of mast cells  
Mature mast cells originate from multipotent haematopoietic stem cells that commit to 
the mast cell lineage (CD34+, c-kit+, FcεRI-) in the bone marrow (Kirshenbaum et al., 
1991). Progenitor mast cells leave the bone marrow and circulate in the blood as 
CD34+ precusor cells (Kitamura and Ito, 2005). In the presence of specific 
chemotactic signals, such as stroma cell derived factor (SDF)-1α, mast cell 
precursors migrate across the vascular endothelium into peripheral tissues involving 
their chemokine receptor CXCR4 (Lin et al., 2001). Depending on the site of tissue 
infiltration and under the influence of stem cell factor (SCF, a c-kit ligand) mast cell 
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precursors proliferate and differentiate either into connective tissue-type or mucosal-
type mast cells (Costa et al., 1996, Oskeritzian et al., 2005) (figure 3).  
 
 
 
Figure. 3. Mast cell differentiation and maturation 
Diagram illustrating important stages of mast cell differentiation and maturation under 
the influence of SCF. Mast cells differentiate from the hematopoetic progenitors in 
the bone marrow to pro-mastocytes, which enter the blood vessel and finally mature 
in the peripheral tissue, especially in the vicinity of blood vessels. 
 
1.3.3.2. Mast cell activation 
The two known pathways of mast cell activation are IgE dependent and IgE 
independent pathways. IgE dependent is the widely known pathway of mast cell 
activation through its high affinity receptor FcεRI (Blank et al., 1989). Cross-linkage of 
IgE by direct interaction of IgE with allergens initiates mast cell activation. The 
pathways that are IgE independent do not involve the mast cell receptor FceRI. They 
are activated by polybasic molecules, such as compound 48/80 and by polymyxin B 
(Lagunoff et al., 1983), by neuropeptides such as substance P, nerve growth factor, 
neurotensin and vasoactive intestinal polypeptide (Mazurek et al., 1986, Li et al., 
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2012) and also by reactive oxygen species (Brooks et al., 1999, Santos et al., 2000). 
Mast cells have the ability to release several mediators, which initiate both 
immunological and non-immunological responses. However, it is so far unknown, 
whether mast cells are activated during arteriogenesis.  
 
1.3.3.3. Mast cell derived mediators 
Mast cells contain a wide variety of preformed mediators that are secreted upon mast 
cell activation. These preformed mediators include histamine, proteases (i.e. tryptase 
and chymase), growth factors (i.e. platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF)-2 and transforming growth factor (TGF)-ß) and cytokines (i.e. 
tumor necrosis factor (TNF)-α, monocyte chemoattractant molecule (MCP)-1, and 
granulocyte monocyte–colony stimulating factor (GM-CSF)). Most of these mediators 
have been shown to promote arteriogenesis when applied exogenously (Schwartz et 
al., 1987, Falus and Meretey, 1992, Qu et al., 1995, Ito et al., 1997, Buschmann et 
al., 2001, Hoefer et al., 2002, Cao et al., 2003, Grundmann et al., 2005, de Paula et 
al., 2009). In addition to the preformed mediators, activated mast cells also produce 
lipid mediators of which prostaglandins and leukotrienes are the major ones (Boyce, 
2007) (figure 4). However, the contribution of these mast cell mediators in 
arteriogenesis is still unknown. 
10 
 
 
 
Figure 4: A sketch diagram summarising different activators and inhibitors of mast 
cells and mediators released by mast cells.  
ROS for reactive oxygen species; C48/80 for compound 48/80; FGF-2 for fibroblast 
growth factor-2; PDGF-BB, for platelet-derived growth factor-BB; TGF-ß for 
transforming growth factor-ß; MMP for matrix metalloproteinase; TNF-α for tumor 
necrosis factor α; MCP-1 for monocyte chemoattractant protein-1 and (GM-CSF for 
granulocyte monocyte-colony stimulating factor.  
 
1.3.3.4. Mast cells in the vascular wall 
Mast cells are localized in the close vicinity of the vascular wall. This location of mast 
cells in the perivascular space is promoted by the endothelial cell release of SCF 
(Mierke et al., 2000). Mast cells were first detected by (Wolf et al., 1998) in the 
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adventitia of growing collaterals, however, so far no study has investigated the role of 
mast cells in arteriogenesis.  
 
1.3.3.5. Mast cells,  tissue remodelling and cardiovascular diseases 
Mast cell proteases such as tryptase and chymase directly degrade the connective 
tissue matrix of the vascular wall (Saito, 2005). In addition, the release of tryptase 
from mast cells activates the latent matrix-degrading metalloproteases to active 
MMP-2 and 9 (Gruber et al., 1989). Tryptase, chymase and MMPs altogether digest 
tissue matrix, collagen and internal elastic lamina of blood vessels, which is essential 
for tissue remodelling and repair. Furthermore, MMP-2 and 9 have been described to 
be involved in arteriogenesis (Cai et al., 2000).  
A correlation between mast cells and MMP has been reported in a study which 
showed a significant increase in the number of mast cells and in MMP activity and 
concomitant fibrillar collagen degradation after the experimental induction of an 
aortocaval (arterial venous) fistula in rats. Such an increase was prevented by a 
treatment with cromolyn, a mast cell stabilizing drug (Marone et al., 1995, Patella et 
al., 1997, Brower et al., 2002). In addition, increased numbers of cardiac mast cells 
have been reported in patients with end-stage cardiomyopathy (Marone et al., 1995) 
and in animal models of hypertension (Panizo et al., 1995), mitral regurgitation 
(Dell'italia et al., 1997), and myocardial infarction (Engels et al., 1995). However, the 
contribution of mast cells in vascular remodelling during arteriogenesis has yet to be 
investigated. Since mast cells are capable of synthesizing and releasing several 
important mediators of tissue remodelling as well as growth factors, the general aim 
of the study was to investigate the functional role of mast cells in arteriogenesis. 
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1.4. Aim of the study 
Arteriogenesis, the growth of pre-existing arteriolar anastomosis into natural 
bypasses substituting for an occluded artery, is well known to be dependent on 
monocytes supplying growth factors and cytokines to the growing vessel.  
Monocytes, however, have to be recruited to the perivascular space. Wolf et al. have 
found that mast cells are localized in the perivascular space growing collateral 
arteries (Wolf et al., 1998). From the literature it is known that mast cells contain a 
variety of factors that promote arteriogenesis when applied exogenously (e.g. FGF-2, 
TNF-α and MCP-1) (Ito et al., 1997, Hoefer et al., 2002, de Paula et al., 2009). 
Therefore, the aim of this study was to investigate whether mast cells play a role in 
arteriogenesis and if yes,  
a. What is the functional role of mast cell in arteriogenesis? 
b. What triggers mast cell degranulation during arteriogenesis? 
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2. MATERIALS AND METHODS  
Animal care and experimental procedures were performed in strict accordance with 
the National Institute of Health animal registration guidelines and were approved by 
the local animal care committee (Regierung von Oberbayern; Germany; protocol 
number Gz.55.2-1-54-2532-73-12). Animals and animal-derived materials were 
treated in accordance with the guide for the care and use of laboratory animals 
(National Institutes of Health, Publication No.85-23, revised 1996) 
 
2.1. Materials 
2.1.1.  Animals 
Wildtype (SV129) mice were obtained from the Walter Brendel Institute, and C57Bl6 
were purchased from Charles River Laboratories, Sulzfeld, Germany.  
Urokinase plasminogen activator (uPA)-/- and NADPH oxidase 2 (Nox2; gp91phox; 
B6.129S6-Cybbtm1Din/J)-/- mice were a generously gift from from Christoph A 
Reichel from Walter Brendel Centre for Experimental Medicine, Munich Germany and 
from Norbert Weissmann of Justus-Liebig-University Giessen, Giessen Germany 
respectively. Both uPA-/- and Nox2-/- mice were breed originally from Charles River 
Laboratories, Sulzfeld, Germany. (Reichel et al., 2011, Schulz et al., 2014) 
 
2.1.2. Femoral artery ligation 
Surgical instruments 
1. Suture, Vicryl 6,0 and Perma Hand Seide 4,0, ETHICON (Norderstedt, 
Germany) 
2. Non sterile REEL silk 002, PEARSALL LIMITED (Taunton, UK) 
3. FORCEPS SCIENCE TOOLS (Heidelberg, Germany) 
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4. FINE FORCEPS SCIENCE TOOLS (Heidelberg, Germany) 
5. FINE SCISSORS SCIENCE TOOLS (Heidelberg, Germany) 
6. Scalpel No. 20, FEATHER (Osaka, Japan) 
7. Compress, NOBA VERBANDMITTEL (Wetter/Ruhr, Germany) 
8. Cotton-tipped applicators (Puritan, Hardwood Products) 
9. Temperature control unit with heating pad, FHC (Bowdoinham, USA) 
10. Microscope stemi DV4 Spot, ZEISS (Jena, Germany) 
11. Light source KI 1500, SCHOTT (Mainz, Germany) 
12. Venofix 25G, B.BRAUN (Melsungen, Germany) 
13. Injection cannula 27G and 30G, B.BRAUN (Melsungen, Germany) 
14. Syringe 5 ml, B.BRAUN (Melsungen, Germany) 
15. Syringe 1 ml, Microlance 23G, BECTON DICKINSON (Franclin Lakes, USA) 
16. Falcon Tubes, 15 ml and 50 ml, BECTON DICKINSON (Franclin Lakes, USA) 
17. Cryotube Vials, NUNC (Roskilde, Denmark) 
18. Aluminium foil 
 
Materials and chemicals 
1. Sodium chloride solution 0,9%, B.BRAUN (Melsungen, Germany) 
2. Cutasept F, BODE CHEMIE (Hamburg, Germany) 
3. Bepanthen eye and nose cream, BAYER (Leverkusen, Germany) 
4. Latex, CHICAGO LATEX (Chicago, USA) 
5. Dry ice 
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   Anaesthesia: 
1. Medetomidin 1 mg/ml, Dorbene Vet®, FORT DODGE/PHIZER (New York, 
USA)  
2. Midazolam 15mg/3ml, RATIOPHARM (Ulm, Germany) 
3. Fentanyl® 0,5 mg, JANSSEN-CILAG (Neuss, Germany) 
Neutralisation: 
1. Altipamezol 1 mg/ml, Revertor®, CP-PHARMA (Burgdorf, Germany) 
2. Naloxon 0,4 mg/ml, INRESA (Freiburg, Germany) 
3. Flumazenil 0,1 mg/ml, INRESA (Freiburg, Germany) 
 
Laser Doppler imaging technique 
1. Laser Doppler, moorLDI2-IR, MOOR INSTRUMENTS (Wilmington, USA) 
2. Isoflurane vaporiser, ABBOTT (Chicago, USA) 
3. Heating chamber (self constructed) 
4. Two-sided tape Nupi, tesa SE (Hamburg, Germany) 
 
2.1.3. Substances used for treatment 
1. 0.9% saline (NaCl(aq)): B.Braun Meisungen AG Cat No. 34209 
2. Compound (C) 48/80: Sigma Aldrich Cat No. C2313 
3. Diprotin A (Ile-Pro-Ile): Sigma Aldrich Cat No. I9759  
4. Sodium cromoglycate (cromolyn): Sigma Aldrich Cat No. C0399  
5. Stem cell factor (SCF): ImmunoTools Cat No. 11343325 
6. PR-68570: Tocris bioscience Cat No. 1635  
7. N-acetylcystein (NAC): Sigma Aldrich Cat No.  A7250  
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8. Ly6G; neutrophil antibody (1A8): BioXcell Cat No. BE0075-1  
9. Apocynin:  Santa Cruz Biotechnology, sc-203321  
2.1.4. Visualization of the hind limb 
1. Polysciences, Inc. Batson’s No. 17 Plastic Replica and Corrosion Kit. 
Cat.No. 07349) 
2. Maceration solution (Fa. Polysciences, Inc Cat.No. 07359) 
 
2.1.5. Histology and Immunohistochemistry 
Instrumentation 
1. Embedding casettes, 70071-series, ELECTRON MICROSCOPY SCIENCES 
(Hatfield, USA) 
2. Tissue processors for histology, Shandon Hypercenter XP, THERMO 
ELECTRON 
3. CORPORATION (Pittsburgh, USA) and Tissue-Tek® VIPTM, SAKURA (Tokyo, 
Japan) 
4. Embedding station, AP280-1, MICROM/ THERMO FISHER SCIENTIFIC 
(Rockford, USA) 
5. Sliding microtome, JUNG (Heidelberg, Germany) 
6. Microscope slides (Menzel), superfrost Plus, THERMO FISHER SCIENTIFIC 
(Rockford, USA) 
7. Tissue Stainer COT 20, MEDITE (Burgdorf, Germany) 
8. Leica DMD108 microscope with an integrated camera, LEICA (Wetzlar, 
Germany) 
9. ImageJ software, version 1.45. (Wayne Rasband, NIH, USA) 
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Chemicals 
1. Phosphate buffered formalin 4% (PFA), in-house pharmacy 
2. Ethanol 70%, 96% and 100%, in-house pharmacy 
3. Xylol55, MERCK (Darmstadt, Germany) 
4. Xylene, MERCK (Darmstadt, Germany) 
5. H202 7,5%, MERCK (Darmstadt, Germany) 
6. TRS 6, DAKO (Glostrup, Denmark) 
7. Target Retrieval Solution, DAKO (Glostrup, Denmark) 
8. Avidin-biotinylated enzyme complex rat IgG, VECTOR (Burlingame, USA) 
9. Hematoxylin Gill’s sedimentary coeffcient formula, VECTOR (Burlingame, 
USA) 
10. Kaiser sedimentary coefficient glycerol gelatin, VECTOR (Burlingame, USA) 
11. ImmPress Reagent Kit anti-goat IgG, VECTOR (Burlingame, USA) 
12. Streptavidin AP, VECTOR (Burlingame, USA) 
13. Chromogen red, AEC (Fa. Invitrogen, Cat. No. 00-1122) 
14. Dako ArkTM Peroxidase Kit, DAKO (Glostrup, Denmark) 
15. Vectastatin ABC-Kit Elite Rat IgG (Fa. Vector, Cat. No. PK6104) 
Haematoxylin and Eosin staining 
1. Haematoxylin (Fa. Merck Cat.No. 1.09249.2500)  
2. Eosin solution (Fa. Chroma Cat.No. 2C 140) 
Giemsa staining 
1. May-Grünwald solution (Merck cat No. 1.01424) 
2. Giemsa solution (Fa. Applichem, Cat.No. A0885) 
Primary and secondary antibodies 
1. CD45, rat anti-mouse, Fa. BD PHARMINGEN, Cat. No. 550539  
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2. Ki67, rat anti-mouse, Fa. Dako, Cat No. M7249 
3. CD31 rat anti-mouse, Fa. Santa Cruz Biotechnology, Cat.No. sc-1506 
4. Secondary antibody, biotinylated anti-rat IgG (Fa. Vector, Cat.No. BA 4001).  
 
Buffers and solution preparation 
1. Adenosine phosphate buffered saline, containing 0,1% adenosine, SIGMA-
ALDRICH (St. Louis, USA) and 0,05% bovine serum albumin, SIGMA-
ALDRICH (St. Louis, USA) 
2. 1L of 10x Tris Buffered Saline (TBS): 
-24.2 g Trizma base (C4H11NO3) and 80 g sodium chloride (NaCl) to 1 L of 
distilled water. pH adjusted to 7.6 using concentrated HCl. 
3. 1L of 10x Phospahte Buffered Saline (PBS): 
-80g of NaCl, 2g of KCl, 14.4g of Na2HPO4 and KH2PO4 were added in 1L of 
distilled water and finally adjusted to a pH of 7.4. 
4. 1L of antigen retrieval, 10mM citrate buffer 
-2.94g of sodium citrate trisodium salt dehydrate (C6H5Na3O7.2H2O) were 
added to 1L of distilled water and the pH adjusted to 7.4. 
5. 3% Hydrogen Peroxide.  
-10 ml of 30% H2O2 were added to 90 ml of distilled water. 
6. 5% BSA 
-5mg of bovine serum albumin were added to 100ml of distilled water. 
7. 2.5 ml of ABC-kit solution. (Vectastatin ABC-Kit Elite Rat IgG (Fa. Vector, Cat. 
No. PK6104) 
-1 drop of solution A was added to 2.5ml of PBS followed by vortex, then one 
drop of substance B was added and again the solution were vortexed. 
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8. 5ml of chromogen AEC-kit. (Fa. Invitrogen, Cat. No. 001122) 
-2 drops of buffer, 3 drops of AEC and 3 drops of H2O2 were added to 5 ml of 
distilled water and vortexed. 
9. Cell-Lysis-Buffer 
    -25mM Tris (Ph 7.5) 
-1% Triton X-100 
          -0,5mM Ethylenediaminetetraacetic acid (EDTA) 
-150mM Sodium chloride NaCl 
-10mM Sodium Fluoride (NaF) 
-1% Phenylmethanesulfonyl fluoride (PMSF) 
 
2.1.6.  Antibodies and isotopes controls used in fluorescence-activated cell 
sorting (FACS) 
S/N Antibodies colour Amount Company Expression  
1 CD45 clone APC-Cy7 1µl BD. Cat.No. 557659 leukocytes 
2 CD11b clone FITS 1µl eBioscience. 
Cat.No. 11-0112 
Monocytes, 
granulocytes, 
macrophages 
and activated 
lymphocytes 
3 Gr-1 clone PE 0,2µl BD. Cat.No. 553128 Neutrophils 
4 CD115 clone APC 0,3µl eBioscience. 
Cat.No. 17-1152 
Monocytes and 
macrophages 
5 CD8a clone PE-Cy5 1µl eBioscience. 
Cat.No. 25-0081 
CD8 T-cells, 
thymocytes 
6 CD4 clone AlexaFluor700 1µl eBioscience. 
Cat.No. 56-0041 
CD4 T- cells 
7 F4/80 clone eFluor450 2.5µl eBioscience. 
Cat.No. 48-4801 
Macrophages 
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Isotypes controls 
S/N Isotypes colour Amount/probe Company 
1 IgG2bk APC-Cy7 1µl BD. Cat.No. 552773 
2 IgG1k FITS 1µl eBioscience. Cat.No. 11-4301 
3 IgG2bk PE 0,2µl BD. Cat.No. 553989 
4 IgG2ak APC 2,5µl eBioscience. Cat.No. 17-4321 
5 IgG2ak PE-Cy5 1,25µl eBioscience. Cat.No. 45-4321 
6 IgG2bk AlexaFluor700 0.625µl eBioscience. Cat.No. 56-4031 
7 IgG2ak eFluor450 2.5µl eBioscience. Cat.No. 48-4321 
 
- BD FACS-Lysing solution: BD biosciences Cat No. 349202 
- Collagenase II: Biochrom Cat No. C2-22 
- FACS machine: Beckman coulter, Gallios flow cytometer 2/8 
- Analysis software:  Kaluza version 1.2 
 
2.1.7. Commercial kits for MMP, TNF-alpha, MCP-1, SDF-1alpha
 
and serum 
protein array 
The procedures of the commercial kits are unique and were performed 
according to the individual manufacturer’s instructions  
a)  SensoLyte 520 Generic MMP Assay Kit *Fluorometric* (Fa. AnaSpec, Cat No. 
71158). 
b) Mouse TNF alpha ELISA Ready-SET-Go!® Catalog Number: 88-7324 
c) Mouse MCP-1 ELISA Ready-SET- Go!® Catalog Number: 88-7391 
d) Mouse CXCL12/SDF-1alpha Immunoassay; Cat. No. MCX120 (serum) 
e) Mouse SDF-1alpha ELISA Kit; Cat. No. ELM-SDF1alpha-001 (collaterals)  
f) Mouse serum protein array; Proteome Profiler TM Mouse angiogenesis 
antibody array. (Fa R$D Systems, Cat No. ARY015).   
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2.1.8. RNA extraction 
Material: 
-TRIzol (Ambion, Life technologies, 155596026, store at RT) 
-Chloroform (Sigma-aldrich 372978, store at 4ºC) 
-Phenol solution, saturated with 0,1M citrate buffer  pH4,3 (Sigma-aldrich P4682, 
store at 4ºC) 
-Isopropanol (Sigma-Aldrich, I9516) and 70% and 80% Ethanol (Sigma-Aldrich, 
I485143932) diluted with pure H2O (Aqua injectabilia) (4ºC, -20ºC) 
-RQ1 DNase I Promega (M6101) 
-10mM Tris HCl pH 7,5 
RNeasy MinElute cleanup kit (74204, Qiagen) 
 
Machines 
-Homogenisator Speed Mill PLUS from Analytik Jena 
-Eppendorf centrifuge: (Cat No. 5424, Hamburg, Germany). 
-Eppendorf BioPhotometer (Eppendorf, 6915636) 
2.1.6. cDNA synthesis and qRT-PCR 
Material: 
1st strand cDNA synthesis kit (Roche, 11483188001) 
RNA samples 
Power Sybr Green master mix (Life technologies, 4368577) 
Machines 
-Thermal Cycler 2720 Applied Biosystems 
-StepOnePlus (Life technologies, 5835124) 
Analysis software: StepOne software version 2.2.2 
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a. Primers 
Primer Sequence (5'--> 3') 
18s forward 5`-GGACAGGATTGACAGATTGATAG-3` 
18s reverse 5`-CTCGTTCGTTATCGGAATTAAC-3` 
MCP1 forward 5`-CTCAAGAGAGAGGTCTGTGCTG-3` 
MCP1 reverse 5`-GTAGTGGATGCATTAGCTTCAG-3` 
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2.2. Methods 
2.2.1. Surgical procedures to induce arteriogenesis 
General anaesthesia was induced in mice by a sub-cutaneous injection of a 
combination of midazolam (5 mg/kg), medetomidine (0.5 mg/kg) and fentanyl (0.05 
mg/kg). The depth of anaesthesia was controlled and accepted if the response to a 
toe pinch was absent. Mice were monitored with a rectal probe and body temperature 
was maintained at 37°C with a homoeothermic heating pad connected to a rectal 
temperature probe (FCH-BOWNDOINHAM, ME04008 USA). Both inguinal regions 
were sprayed with skin disinfectant and the hairs were shaved with a sterile surgical 
blade. Afterwards mice were fixed on a working table using sole tapes with the foot 
sole facing upward in order to expose the inguinal areas. 
The skin in the inguinal area was opened on either side by a surgical incision. The 
underlying fat tissues were placed aside with minimal tissue damage and without injuries 
of the vessels. Under a light microscope, the femoral artery, veins and nerves were 
exposed. The femoral artery was then separated and a loop was made around the 
femoral artery with a suture (7/0 braded).  On the right limb the suture was tightened 
with three nods distal to the a. profunda femoris branch and proximal to the a. genu 
descendens.  On the left sham operated side, the suture was placed under the 
vessel without a nod and remained there. Finally, the skin was sutured using 
6/0Vicryl on either side after the wound had been irrigated with sterile normal saline. 
Mice were then injected sub-cutaneously with an antidote using a mixture of Naloxon, 
Flumazenil and Antipamezol, and left freely to recover.  
 
 
 
24 
 
2.2.2. Experimental design   
Arteriogenesis was induced in 6 – 8 weeks old mice by surgical occlusion of 
the right femoral artery distal to the a. profunda femoris and proximal to the a. genu 
descendens (figure 1). On the left, the sham operated side, the suture was placed 
loosely under the femoral artery but no nod was tied. Mice were randomly assigned 
to control and experimental groups, as follows: in the control group, mice were 
treated with 50µl of a 0.9% saline (NaCl(aq)) injected either subcutaneously in the 
inguinal region of both hind limbs or intraperitoneally corresponding to the rout of 
treatment in the experimental group. Experimental mice were subjected to different 
treatments in which the researcher was non-blinded: a first group received daily 
intraperitoneal (i.p.) injections of a mast cell stabilizer (cromolyn, 20mg/kg per day, 
(Liao et al., 2010)) starting 3 days prior to ligation until day 20 after ligation. A second 
group received i.p. injections of diprotin A (70 µg/kg/day), a substance known to 
enhance SDF-1α levels due to inhibition of enzymatic activity of dipeptidylpeptidase 
(DPP) IV (Zaruba et al., 2009, Zhang et al., 2010), twice a day starting 3 days prior to 
ligation until day 20 after ligation. A third group received subcutaneous injections in 
the right and left inguinal region of compound (C) 48/80 (1mg/kg/inguinal region, 
(Tang et al., 2009)), a mast cell degranulator, immediately after ligation, at days 1, 2 
and 3 and again at days 7, 8 and 9 after ligation. A forth group received i.p. injections 
of stem cell factor (SCF; 50µg/kg/day, (Keller et al., 2006)), which promotes mast cell 
differentiation and proliferation, once a day starting 3 days before ligation until day 20 
after ligation. A fifth group received diprotin A + cromolyn and a sixth group received 
a combination of C 48/80 + diprotin A. A seventh group received a combination of 
diprotin A + C 48/80 + SCF (figure 5 and 6). Other substances were also applied, 
including an inhibitor of substance P release (RP-67,580; 2mg/kg  i.p. twice a day 
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starting 3 days before ligation (Kennedy et al., 1997)), an inhibitor of the NADPH 
oxidases (apocynin; 0.25mg/ml = 50mg/kg/day in drinking water; starting 3 days 
before ligation (Sovari et al., 2008, Liu et al., 2013). N-acetylcystein an anti-oxidant 
through increasing cellular glutathione levels (Zafarullah et al., 2003, Reliene et al., 
2004) was also added to the drinking water (6 mg/ml =1g/kg/day; starting 3 days 
before ligation). Urokinase plasminogen activator (uPa; 0.2mg/kg; intramuscular 
injection, (Reichel et al., 2011)) was applied once after femoral ligation. The 
neutrophil depletion antibody 1A8 (100 µg/kg) was injected i.p 2 days before ligation, 
immediately after ligation and again at days 2, 4 and 6 after ligation (Drechsler et al., 
2010).  
 
 
Figure 5. Showing images of mast cell(s) in response to the application of different 
substances.  Dipeptidylpeptidase (DPP)-IV, stromal cell derived factor (SDF)-
1α, Compound (C) 48/80.  
 
2.2.3. Measurements of hind limb blood flow 
Blood flow in the distal hind limbs of mice was recorded in vivo with a Moor Laser 
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Doppler Perfusion Imager (MLDI 5063, Moor Instruments Ltd., Devon, UK). For 
these measurements, mice were first anaesthetized with 1.5% of isoflurane 
supplemented with 2.0 l/min of oxygen and then placed in supine position in a 
temperature-regulated chamber (37°C) for 10 minutes before the onset of 
measurements. A laser Doppler imager was used to quantify the blood flow in the 
plantar surface within defined regions of interest (ROIs). The ratios of occluded over 
non-occluded ( s h a m )  values were recorded for comparison between control and 
experimental groups. Measurements were performed before, immediately after 
ligation and at days 3, 7, 14 and 21 after ligation (figure 6). In one of the 
experiment, the measurement was performed at 6, 12, 24 and 48 hours after femoral 
ligation. After the last laser Doppler measurements, animals were anaesthetized with 
isoflurane and killed by cervical dislocation. 
 
 
 
 
A 
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Figure 6. LDI perfusion measurements in the distal hind limb and application of 
substances:  
(A) Experimental setting of hind limb perfusion measurements showing: 1. 
Isoflurane gas jar which supplies isoflurane, 2. Regulated heating chamber 
(37°C), 3. Laser scanner, 4. Processor, 5. Programmed computer recording 
the scanned hind limb blood flow images for measurements. 
(B) Laser Doppler scan images of hind limbs of mice showing progressive 
blood flow perfusion recovery on the occluded side (left) at different time points 
before occlusion, after femoral artery ligation (fal) and at days 3, 7, 14 and 21 
in comparison to sham operated side (right – constantly perfused with blood).  
And application of  
& Compound 48/80 (1mg/kg subcutaneous in the left and right inguinal region 
starting immediately after ligation until day 3, then day 7 to day 9) -> 
degranulation of mast cells.  
* SCF (50µg/kg/day i.p.daily starting 3 days before ligation) -> maturation of 
mast cells.  
* Diprotin A (70µg/kg/day i.p. daily starting 3 days before ligation) -> SDF-1α  
-> recruitment of mast cells.  
* Cromolyn (20mg/kg/day i.p. daily starting 3 days before ligation) -> blocking 
of mast cell degranulation.  
 
2.2.4. Visualization of the hind limb arterial system   
For a visualization of the hind limb arteries, we produced plastic replica of the hind 
limb arterial system. Seven days after femoral artery ligation mice were 
B Ligation (fal) 
* &
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anaesthetised and the hind limbs were perfused with cast solution (Polysciences, Inc. 
Batson’s No. 17 Plastic Replica and Corrosion Kit. Cat.No. 07349) via an aortic 
cannula. The cast solution was prepared by dividing the monomer base solution A 
into two parts (10ml each). Afterwards the pigment was added to base solution A in 
the amount of 10% and stirred vigorously prior to adding the catalyst and promoter. 
To the first part we added 4 ml of catalyst and stirred the mixture. To the second part 
we added 3 drops of promoter C to base solution A and mixed slowly with a magnetic 
stirrer. Finally the two solutions were added together and stirred. The final solution 
was then injected with a cannula and a 20 ml polyethylene syringe. The specimens 
were then kept in cold ice for 3 hours before we placed them at 50°C in a maceration 
solution (Fa. Polysciences, Inc Cat.No. 07359) for about 3 hours to corrode.  
Afterwards, the muscle tissue was slowly removed and the images were captured 
using Leica microscope M 205 FA. 
2.2.5. Tissue perfusion, fixation and isolation  
For molecular genetic studies and histological analysis, we isolated collateral arteries 
as well as adductor and gastrocnemius muscles of the hind limbs of control and 
experimental mice. Mice were anaesthetized, placed in supine position under the 
microscope with the limbs spread and fixed. For molecular biological studies, the 
abdominal cavity was opened to expose the abdominal aorta below the renal 
branches and to separate it from fat tissue. Then the aorta was cannulated (figure 7 
A) and the inferior vena cava was cut. Catheters were made from a winged infusion 
set cutting off the tip of the needle and blunting the end of the needle. A white latex 
contrast medium (compound of natural and synthetic latex; Chicago latex, Crystal 
lake, IL 60039) was then injected through the catheter (figure 7 B). Collateral arteries 
from experimental and control animals were excised, snap-frozen, and stored at 
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−80°C for further investigations.  
 
 
 
 
Figure 7. Isolation of hindlimb collaterals 
(A). Images showing several cannulation steps in the abdominal aorta. (B). Images 
showing superficial collateral arteries 7 days after ligation (left) and sham operated 
limb (right). The contrast medium latex (white) was injected for visualization of 
collaterals during isolation.  
For isolation of adductor and gastrocnemius muscles for histological analyses, the 
cannula was inserted through a small cut in the abdominal aorta and the hind limb 
vessels were perfused for 3 minutes with a dilatation buffer containing 0.1 % 
adenosine (Sigma) and 0.5 % bovine serum albumin (BSA; Sigma) in phosphate-
buffered saline (PBS; with pH 7.4). Adductor muscles of both hind limbs (ligated and 
non-ligated) were cut in a triangular comprising the area supplied by collaterals of the 
femoral artery. The basis of the triangle was cut proximally to the A. profunda 
femoris. The other side was cut laterally from the A. femoralis towards the knee, and 
the third side connecting the knee with the medial side of the A. profunda femoris 
A 
B 
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(figure 8 A and B). The gastrocnemius muscle was isolated by cutting the two heads 
located close to the knee joint and by detaching the muscle from its distal attachment 
via the Achilles tendon (figure 8 C).  
 
Figure 8: Isolation of hind limb adductor and gastrocnemius muscles. 
A: Triangular cut during the isolation of adductors (AD) as seen by red dots.  
B: After isolation of adductor muscle from the mouse hind limb.  
C: Isolation of gastrocnemius (GC) muscle.  
 
 
2.2.6. Histology and immunohistochemistry 
 
For a detailed microscopic examination of adductor and gastrocnemius muscles, we 
prepared histological sections for an assessment of perivascular mast cells, for 
collateral diameter measurements and for an analysis of the tissue damage in the 
distal hind limb. In addition, for an identification of perivascular leukocytes, vascular 
cell proliferation and capillaries we performed immunohistochemical experiments.  
Isolated adductor muscles were fixed in 4% parafomaldehyde solution for 30 
minutes. Then the muscles were washed with running tap water and immersed in 
70% alcohol for 24 hours. The adductor and gastrocnemius muscles were processed 
in an automatic tissue processor (Thermo Fischer Scientific; Shandon citadel 1000, 
Dreieich, Germany) for 12 hours. Tissues were cut transversally in 2 mm thick probes 
Achilles GC 
AD 
GC 
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and placed in labeled embedding cassettes containing liquid paraffin. The paraffin in 
the cassettes was left to solidify on a cooling plate (-4°C) for 30 minutes. For 
histological and immunohistological analysis, tissues were sectioned in 5µm thick 
slides using a CM 3000 cryomicrotome (Leica, Germany) and placed on microscope 
slides. The slides containing the sections were left to dry at room temperature for 24 
hours before further processing. 
2.2.6.1. Histology 
The slides containing the sections were placed in a rack then followed by a series of 
washes to remove the paraffin (deparaffinization): 
1.  Xylene 2: for 5 minutes  
2.  Xylene 1:1 with 100% ethanol: 5 minutes  
3.  100% ethanol: 15 minutes  
4.  96% ethanol: 15 minutes  
5.  70 % ethanol: 15 minutes   
6.  Then washed in running cold tap water to rinse and to avoid drying of the 
sections. 
 
 
2.2.6.1.1. Haematoxylin and eosin staining 
For morphological identification and measurement of collateral diameters as well as 
distal hind limb tissue damage, we stained the tissues with haematoxylin and eosin.  
After deparaffination, 5µm sections were immersed in haematoxylin (Fa. Merck 
Cat.No. 1.09249.2500) for 1 minute and then rinsed with tap water until the running 
water was clear. Subsequently the sections were transferred in an eosin solution (Fa. 
Chroma Cat.No. 2C 140) for 1-2 minutes and then rinsed with tap water until the 
running water was clear. Afterwards slides were dehydrated in ascending alcohol 
solutions (70% for 3 min, 96% for 3 min, 100% for 5 minutes), and then cleared with 
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xylene (2 X for 10 minutes).  Finally the slides were mounted on cover slip onto a 
labeled glass slide using Eukit (Fa. O. Kindler GmbH & Co) for histological 
examination. 
2.2.6.1.2. Giemsa staining 
In order to identify and quantify degranulated and non-degranulated mast cells in the 
region around collateral arteries, both adductor and gastrocnemius muscles were 
stained with Giemsa. Following deparaffination, 5µm sections were immersed in 
May-Grünwald solution (ratio of 1:8 with distilled water; Merck cat No. 1.01424) for 10 
minutes and then washed with running tap water. The slides were then stained with 
Giemsa (Fa. Applichem, Cat.No. A0885) for 6 minutes, washed with running tap 
water and counterstained with 1.5% acetic acid. Afterwards, the stained tissues were 
subsequently transferred in ethanol (75% then 95% and then 100%; 1-2 minutes 
each). The slides were then transferred to xylene for about 5 minutes followed by 
mounting with cover slips using eukit. Degranulating mast cells were identified by the 
presence of stained granules outside of its cell membrane.  
2.2.6.2. Immunohistological staining 
With the help of immunohistology I stained tissue sections of adductor for an 
identification of perivascular leukocytes and for the detection of vascular cell 
proliferation. In the gastrocnemius muscles I investigate the number of capillaries per 
muscle fibre and for the detection of leukocyte infiltration in the gastrocnemius 
muscle. 
For a heat induced epitope retrieval, a pressure cooker containing a target retrieval 
buffer (citrate buffer pH 6.0; Fa.Dako,Cat.No. S1699) at a molar concentration of 10 
mM was placed on a hot plate to boil. The slides were then immersed in a boiling 
citrate buffer for 10 minutes until the cooker reached full pressure. Then the rack was 
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removed and the slides were cooled at room temperature for 20 min followed by 
washing twice in 10 x tris buffered saline (TBS) at pH 7.6.  
2.2.6.2.1. Ki67 staining 
Ki67 was used to identify proliferating endothelial and smooth muscle cells of 
collaterals in the hind limbs. Following antigen retrieval, sections were incubated in 
3% hydrogen peroxide (H2O2, Roth, cat # 7070.1) for 15 minutes and then washed 
twice in 10 x TBS.  Each section was then blocked with 100µl of 5% bovine serum 
albumin (BSA) for 1 hour. The blocking solution was removed and the sections were 
incubated with 200µl of a primary antibody Ki-67 (Fa. Dako, Cat.No. M7249) in a 
1:100 dilution over night at 4°C. The next day, sections were removed from 4°C to 
room temperature and 1 hour later they were washed with 10 x TBS for 5 minutes in 
a shaking plate at a rate of 100/min. The sections were then incubated with 
secondary antibody biotinylated anti-rat IgG (Fa. Vector, Cat.No. BA 4001) in a 1:100 
dilution for 1 hour and then washed again 2 × 5 minutes using 10 x TBS. Sections 
were incubated with ABC-kit solution for 1 hour (Vectastatin ABC-Kit Elite Rat IgG 
(Fa. Vector,Cat. No. PK6104), then washed twice with 10 x TBS. The sections were 
then covered with chromogen red AEC (Fa.Invitrogen, Cat.No. 00-1122) for 10 
minutes, then washed two times with 10 x TBS followed by counterstaining with 
hematoxylin for 10 seconds and mounted with Kaiser glyceringelatin (Fa. Merck, 
Cat.No. 1.09242.0100). Images were taken with a two photon microscope (Leica 
DMD108, Leica Microsystems CMS GmbH, Wetzlar Germany).  
 
2.2.6.2.2. CD45 staining 
For the identification and quantification of perivascular leukocytes in the hind limb 
collaterals and infiltrated leukocytes in the gastrocnemius muscle, tissue sections of 
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adductors and gastrocnemius muscles were stained with CD45. Following antigen 
retrieval, sections were incubated in 3% hydrogen peroxide (H2O2, Roth, cat # 
7070.1) for 15 minutes and then washed twice in 10 x TBS.  Each section was then 
blocked with 100µl of 5% bovine serum albumin (BSA) for 1 hour. The blocking 
solution was removed and the sections were incubated with 200µl of a primary 
antibody CD45 (Fa. Dako, Cat.No. M7249) in a 1:100 dilution over night at 4°C. Next 
day, sections were removed from 4°C to room temperature and 1 hour later they 
were washed with 10 x TBS for 5 minutes on a shaking plate at a rate of 100/min. 
The sections were then incubated with secondary antibody biotinylated anti-rat IgG 
(Fa. Vector, Cat.No. BA 4001) in a 1:100 dilution for 1 hour and then again washed 2 
× 5 minutes using 10 x TBS. Sections were incubated with ABC-kit solution for 1 hour 
(Vectastatin ABC-Kit Elite Rat IgG (Fa. Vector,Cat. No. PK6104), then washed twice 
with 10 x TBS. The sections were then covered with chromogen red AEC 
(Fa.Invitrogen, Cat.No. 00-1122) for 10 minutes, then washed two times with 10 x 
TBS followed by counterstaining with hematoxylin for 10 seconds and mounted with 
Kaiser glyceringelatin (Fa. Merck, Cat.No. 1.09242.0100). Images were taken with a 
two photon microscope (Leica DMD108, Leica Microsystems CMS GmbH, Wetzlar 
Germany).  
 
2.2.6.2.3. CD31 staining 
CD31 was used to identify the sprouting of capillaries endothelial cells in the 
gastrocnemius muscle of both control and experimental animals three days after 
femoral artery ligation. Following antigen retrieval, sections were incubated in 3% 
hydrogen peroxide (H2O2, Roth, cat # 7070.1) for 15 minutes and then washed twice 
in 10 x TBS.  Each section was then blocked with 100µl of 5% bovine serum albumin 
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(BSA) for 1 hour. The blocking solution was removed and the sections were 
incubated with 200µl of a primary antibody CD31 (rat anti-mouse monoclonal CD-31, 
Fa. Santa Cruz Biotechnology, Cat.No. sc-1506) in a 1:100 dilution over night at 4°C. 
The next day, sections were removed from 4°C to room temperature and 1 hour later 
they were washed with 10 x TBS for 5 minutes in a shaking plate at a rate of 
100/min. The sections were then incubated with secondary antibody biotinylated anti-
rat IgG (Fa. Vector, Cat.No. BA 4001) in a 1:100 dilution for 1 hour and then washed 
again 2 × 5 minutes using 10 x TBS. Sections were incubated with ABC-kit solution 
for 1 hour (Vectastatin ABC-Kit Elite Rat IgG (Fa. Vector,Cat. No. PK6104), then 
washed twice with 10 x TBS. The sections were then covered with chromogen red 
AEC (Fa.Invitrogen, Cat.No. 00-1122) for 10 minutes, then washed two times with 10 
x TBS followed by counterstaining with hematoxylin for 10 seconds and mounted with 
Kaiser glyceringelatin (Fa. Merck, Cat.No. 1.09242.0100). Images were taken with a 
two photon microscope (Leica DMD108, Leica Microsystems CMS GmbH, Wetzlar 
Germany). 
 
2.2.7. Fluorescence-activated cell sorting (FACS) 
For the identification and quantification of leukocyte sub-populations in the adductor 
muscles and in the blood, we used the technique of fluorescence-activated cell 
sorting (FACS) with different leukocyte antibody markers. Hind limb adductor 
muscles were isolated from saline (control) and C48/80 + diprotin A treated mice. 
The muscles were mechanically sliced into small 2 – 3 mm pieces and digested using 
collagenase II 1mg/ml in 1% PBS/BSA for 90 minutes at 37°C followed by gentle 
shaking every 30 minutes. The suspension was then filtered with 4 ml of 1% 
PBS/BSA through a 70 µm cell strainer (BD Falcon™), spun 10 min at 1200 g at 
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room temperature and the pellets were finally resuspended in 200 µl of 1% 
PBS/BSA. The samples were incubated with directly conjugated monoclonal 
antibodies against CD45 APC-Cy7, CD11b FITS, Gr-1 PE, CD115 APC, and F4/80 
eFluor450 in dark for 10 minutes at room temperature. Afterwards the samples were 
lysed using 2ml of lysing buffer solution (BD-FACS: Cat.No. 349202) in a dilution of 
1:10 PBS for 10 minutes followed by spinning at a rate of 1200 g. The final pellets 
were resuspended in 200 µl of 1% PBS/BSA in FACS tubes for cytometry. 
Whole blood was collected from the left ventricle using a 1ml syringe containing 0.5µl 
of heparin. 100µl of each blood sample were incubated with directly conjugated 
antibodies against CD45 APC-Cy7, CD11b FITS, Gr-1 PE, CD115 APC, CD4 
AlexaFluor700, and CD8a PE-Cy7 in dark for 10 minutes at room temperature. 
Afterwards erythrocytes were lysed using 2ml of lysing buffer solution (BD-FACS: 
Cat.No. 349202) in a dilution of 1:10 PBS for 10 minutes. The solutions were then 
spun for 10 min at a rate of 1200 g at room temperature. Finally, the pellets were 
resuspended in 200 µl of 1% PBS/BSA.  
We adjusted our flow cytometer settings for adductor muscle and blood probes and 
established a data range for the general autofluorescence from a cell labelled with a 
conjugated antibody. The isotype control conjugated to the same fluorochrome as the 
primary antibody were both run with the same concentration in a FACS machine.  
Isotype controls allowed a distinction between background (non-specific binding) and 
specific binding of the primary antibody. For analysis, the samples were placed in a 
FACS machine (Beckman coulter, Gallios flow cytometer 2/8) and were run 
automatically to obtain different cell populations with respect to the antibody. The 
individual cell populations displays a fluoresence parameter on a light scatter 
cytogram were gated. Therefore the computer was instructed to show and count only 
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the cells that fall in a gated region. The corresponding regions were marked with 
fluoresence antibodies against CD45, CD11b, CD4, CD8, Gr-1, CD115, F4/80. For 
CD11b, CD4 and CD8 positive cells the gating were done after selecting total CD45 
population. Gating for CD115, Gr-1 and F4/80 cell populations was selected after 
gating CD45 positive cells followed by CD11b. Finaly, using Kaluza Software Version 
1.2, we calculate the percentage of each cell type and plot in a graph.  
 
2.2.8. Collateral vessel diameter 
In order to determine the extent of the increase in the vessel diameters, we 
measured the diameters of collateral arteries of the adductor muscles in histological 
sections. Formalin-fixed tissue sections from mice 3 or 7 days after femoral artery 
ligation were processed for routine histopathology. 5-µm-thick paraffin-embedded 
sections were stained with haematoxylin and eosin for evaluating collateral vessel 
morphology and determining the vessel diameters. A computerized image program 
(imaje J 1.45s Wayne Rasband. NIH, USA) was used to calculate the inner and outer 
circumference of four collaterals from each tissue sections under the microscope with 
a screen display. From the mathematical equation ci= πd (where, ci= inner 
circumference, π =3.14 and d=diameter), we obtained the vessel diameter. All values 
were tabulated and saved in Microsoft office excel sheet for analysis.  
 
2.2.9. Quantification of leukocytes  
For a quantification of perivascular leukocytes, tissue sections from adductor muscles 
were stained with CD45 antibody and viewed under a light microscope (Leica 
DMD108) at a magnification of ×400. A digital image was taken from the sections. 
Leukocytes were quantified manually from the microscope with a wide screen display 
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image on individual collaterals. Positive cells (leukocytes) stained against CD45 
antibody were counted in a region around 4 collateral arteries in the tissue sections 
of controls and of mice treated with cromolyn, a combination of Diprotin A + C48/80, 
cromolyn + Diprotin A. An average number of positive leukocytes was counted per 
collateral. Furthermore, muscle sections from the middle part of the gastrocnemius of 
saline (control) and C48/80 + Diprotin A treated mice were also stained against CD45 
antibody and the positive leukocytes were counted per area (mm2). 
 
2.2.10. Quantification of Ki67 or CD31 positive cells 
For a quantification of proliferating endothelial and smooth muscle cells, tissue 
sections from adductor muscles stained with Ki67 antibody were viewed under the 
light microscope (Leica DMD108) at a magnification of ×400, and a digital image was 
taken from the sections. Ki67 positive cells were counted in the four collaterals from 
each tissue section in saline (control), cromolyn, combination of cromolyn + diprotin 
A, and C48/80 + diprotin A treated mice. An average number of positive Ki67 
vascular cells were expressed per collateral. CD31 staining was also performed in 
the gastrocnemius muscle to determine the number of capillaries per fibre in mice 
treated with saline or with C48/80+DipA.  
 
2.2.11. Serum Proteins Antibody Array 
In order to detect specific proteins that are associated with collateral artery growth we 
analysed the serum protein profile. A Proteome Profiler TM Mouse Angiogenesis 
Antibody Array (R&D Systems) was used according to the manufacturer’s protocol. 
The nitrocellulose membranes were first incubated in blocking buffer for 1 hr. A 
cocktail of biotin-labelled antibodies against different individual angiogenesis-related 
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proteins was incubated with 140 µl of serum from mice that were treated with saline 
(control with ligation), saline (control without ligation), or with  C48/80 + diprotin A 
(with ligation). The sample and antibody mixture were then incubated with the 
membranes overnight at 4°C on a rocking platform. After three times washing to 
remove unbound material, the membranes were incubated with horseradish 
peroxidase (HRP) conjugated streptavidin for 30 minutes at room temperature. Then 
the membranes were washed three times before they were transferred to the signal 
detector using an ECL system (Amersham Pharmacia Biotech Aylesbury, UK). The 
array was run in duplicates. The image J software was used to analyse the proteins 
mean pixel density. 
 
2.2.12. Matrix metalloproteinase (MMP) activity assay 
In order to identify the MMP enzymatic activity, we performed kinetic measurements 
of MMP enzymes in the collateral arteries of control and experimental animals. In 
these mice collaterals were homogenised in assay buffer containing 250µl of 0.1% 
(v/v) Triton -X100 at 4°C for 30 minutes. The tissues were then centrifuged (10,000 x 
g, at 4°C, for 15 minutes) and the supernatant was collected and stored at -70°C. 
Pro-MMP containing tissue samples (109 µl) were then activated with 1.1µl of 1mM 
of APMA, which afterwards was incubated for 2 hours in a water bath at 37°C. 50µl of 
the samples and of controls were placed in 96-well plate per well incubated with 50µl 
of MMP-substrate solution. For control, the fluorescence reference standard was 
diluted to 5µM in assay buffer followed by different dilution concentration (2.5 – 
0.3125µM). The tissue samples and control in the plate were allowed to shake gently 
for 30 seconds. For kinetic measurements, the fluorescence signal was measured 
immediately at Ex/Em=490nm/520nm and the data were recorded continuously for 
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60 minutes once a minute. For end-point measurements, the reaction was incubated 
at room temperature for 60 minutes and fluorescence intensity was measured at 
Ex/Em=490 nm/520 nm (Fa. TECAN, Infinite 200, S/N 711003634). A standard curve 
was obtained by plotting the absorbance values against the concentration of the 
standards. Data were normalised to the reference standard curve. 
 
2.2.13. TNF-α analysis 
To quantify the amount of TNF-α in the plasma, we performed TNF-α ELISA in 
plasma of control mice without ligation, in control mice with ligation and in cromolyn 
treated mice. The coating solution was diluted to a final concentration of 1 µg/ml. 100 
µl of the diluted antibody were added to a flat bottomed, high protein binding 96-well 
plate per well, then sealed and incubated at +4°C over night. The coating solution 
was aspirated and the plate washed three times using wash buffer (1x PBS, 0.05% 
Tween-20). 200 µL per well of blocking buffer (1 x Assay Diluents) were added and 
incubated for 1 hour at room temperature. The plate was then emptied. To prepare 
standard concentrations, using 1 x Assay Diluent 2 fold serial dilutions of 1.7 ng/ml of 
TNF-α of the top standard was added to make the standard curve for a total of 8 
points. 100 µL of the plasma samples were added to the appropriate wells, the plates 
were then sealed and incubated at room temperature for 2 hours. The plates were 
then washed four times using washing buffer. 100 µL of detection antibody (biotin-
conjugated antibody) diluted in 1 x Assay Diluent was added in the plate per well, 
sealed and incubated for 1 hour at room temperature. The detection antibody was 
then aspirated and washed four times. Afterward 100 µL of Avidin-Horse radish 
peroxidase (HRP) were added per well and incubated at room temperature for 30 
minutes. The plates were then soaked with wash buffer for 1 to 2 minutes, repeated 
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for 5 times. A substrate solution  (Tetramethylbenzine) was added to each well and 
incubated for 15 minutes at room temperature followed by 50 µL of stop solution (1M 
H3PO4). The absorbance at 450 nm using a microtiterplate spectrophotometer was 
measured. A standard curve was obtained by plotting the absorbance values against 
the concentration of the standards. The concentration of TNF-α in the sample was 
determined by using the standard curve. 
 
2.2.14. MCP-1 ELISA 
To quantify the amount of MCP-1 in the collaterals, we performed MCP-1 ELISA from 
the plasma and from isolated collaterals of C48/80 + diprotin A treated mice and the 
controls. Collaterals were pestled and sonicated under liquid nitrogen. PBS was 
added afterwards to solubilise the collaterals.  
The coating solution was diluted to a final concentration of 1 µg/ml. 100 µl of the 
diluted antibody were added to a flat bottomed, high protein binding 96-well plate per 
well, then sealed and incubated at +4°C over night. The coating solution was 
aspirated and the plate washed three times with 250 µL washing buffer (1x PBS, 
0.05% Tween-20) per well. The residual buffer was removed by placing an absorbent 
paper on the blot plate. The blocking buffer (200µl; of 1 x Assay Diluents) was added 
to each well and incubated for 1 hour at room temperature. The plate was then 
washed once with wash buffer. To prepare standard concentrations, using 1 x Assay 
Diluent 2 fold serial dilutions of 1.7 ng/ml of MCP-1 of the top standard was added to 
make the standard curve for a total of 8 points. 100 µL of the samples were added to 
the appropriate wells, the plates were then sealed and incubated at room 
temperature for 2 hours. Subsequently the plates were washed four times using 
washing buffer. 100 µL of detection antibody (biotin-conjugated antibody) diluted in 1 
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x Assay Diluent was added in the plate per well, sealed and incubated for 1 hour at 
room temperature. The detection antibody was then aspirated and washed four 
times. Afterwards 100 µL of Avidin-Horse radish peroxidase (HRP) were added per 
well and incubated at room temperature for 30 minutes. The plates were then soaked 
with wash buffer for 1 to 2 minutes, repeated for 5 times. 100 µL of substrate solution  
(tetramethylbenzine) was added to each well and incubated for 15 minutes at room 
temperature followed by 50 µL of stop solution (1M H3PO4). The absorbance at 450 
nm using a microtiterplate spectrophotometer was measured. A standard curve was 
obtained by plotting the absorbance values against the concentration of the 
standards. The concentration of MCP-1 in the sample was determined by using the 
standard curve. 
 
2.2.15. SDF-1α ELISA 
To quantify the amount of SDF-1α (i.e. a potent chemoattractant molecule, which 
recruits mast cells and monocytes), we performed SDF-1α ELISA from the serum of 
diprotin A treated mice, or the control without ligation or control with ligation. 50 µL of 
the Assay Diluent was added to each well followed by 50 µL of standard, control or 
samples per well. The mixture were incubated for 2 hours at room temperature on a 
orbital microplate shaker set at 500 rpm. Afterwards, the wells were aspirated and 
washed four times using wash buffer (400 µL). Subsequently, 100 µL of mouse SDF-
1α conjugate was added to each well and incubated at room temperature for 2 hours 
on the shaking plate.  The wells were then aspirated and washed four times using 
wash buffer. The substrate solution (200 µL) was then added to the wells and 
incubated at room temperature in the dark for 30 minutes. Afterwards, 50 µL of stop 
solution was added to each well and the optical density of each well were determined 
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within 30 minutes using microplate reader set to 450 nm. 
 
For quantification of SDF-1α in the collaterals, we performed SDF-1α ELISA from the 
supernatants of isolated collaterals of diprotin A treated mice and controls with 
ligation. The collaterals were placed in 100µL of cell lyses buffer and then treated 5 
times for 2 seconds with ultrasound to dissolve. The samples were then centrifuged 
for 3 minutes at 7000 rpm and the supernatants were collected.  
100 µL of the standard and of the samples were added into appropriate wells. The 
wells were covered and incubated for 2.5 hours at room temperature on an orbital 
microplate shaker set at 500 rpm. Afterwards, the wells were aspirated and washed 
four times using wash solution (300 µL). Subsequently, 100 µL of 1x biotinylated 
antibody was added to each well and incubated at room temperature for 1 hours on 
the shaking plate.  The wells were then aspirated and washed four times using wash 
solution. Afterwards, 100 µL of streptavidin solution was added to each well followed 
by 45 minutes incubation at room temperature with gentle shaking. The solution was 
then discarded and washed three times using wash solution. One-step substrate 
reagent (200 µL) was then added to each well and incubated at room temperature in 
the dark for 30 minutes with gentle shaking. Afterwards, 50 µL of stop solution was 
added to each well and the optical density of each well were determined within 30 
minutes using microplate reader set to 450 nm. For analysis, from both serum and 
collaterals the standard curve was created by plotting the mean absorbance of each 
standard on the y-axis (optical density) against the concentration on the x-axis 
(mouse SDF-1α concentration) and drawing the curve through the points on the 
graph. Therefore, the results were obtained by averaging the duplicate reading for 
each standard, control and sample and the results were subtracted with the average 
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zero standard optical density. 
 
2.2.16. RNA extraction and real-time polymerase chain reaction (RT-PCR)  
For a quantitative analysis of gene expression of the chemoattractant molecule 
(MCP-1) in collateral arteries of the hind limb, we performed both RNA extraction 
followed by qRT-PCR. Total RNA was isolated according to the procedure of 
Chomczynsky and Sacchi (Chomczynski and Sacchi, 1987). 20 mg of collateral 
tissue was homogenised with 300 µl of TRizol in homogenisation tubes for 3 minutes 
and left at room temperature for another 3 minutes. The samples were centrifuged for 
10 min at 12,000 g at 4°C. Afterwards the supernatant was mixed with 60µl of 
chloroform in fresh tubes and shaken vigorously for 15 seconds followed by 
incubation at room temperature for 3 minutes. The mixture was centrifuged for 15 
minutes at 12,000 g at 4°C. The aqueous phase was transferred into a fresh tube 
and 150µl of isopropanol were added. Then the solution was incubated for 10 
minutes at room temperature followed by centrifugation at 12,000 g and at 4 °C. This 
time the supernatant liquid was discarded. The remaining pellets were washed with 
75% ethanol and then again centrifuged at 8,000 g for 5 minutes at 4°C. Then the 
pellets were left to dry for 2 minutes.  
For DNase I digestion, the pellets were resuspended in 48 µl of water and the DNase 
I master mix was added (96µl H2O, 12µl 10xBuffer and 12µl DNase I) and the mixture 
incubated at 37°C for 30 minutes. Afterwards the mixture was cleaned using RNeasy 
MinElute Cleanup kit (Qiagen) as instructed. For RNA purification and concentration 
measurements, 3 µl of RNA solution were diluted to 57 µl of 10mM Tris HCL buffer in 
an eppendorf cuvette. Optical density and concentration of RNA were measured with 
a bio photometer at 260, 280 and 230 nm. 
45 
 
The RNA purity of the sample was calculated using the ratio of 260nm/280nm 
(Protein contamination) and 260nm/230nm (buffer contaminations) 
 260/280 >2  
 260/230 >1,8  
Values above 2 for protein contamination and 1.8 for buffer contamination were 
regarded as pure RNA samples. 
For DNA synthesis we used 1st Strand cDNA synthesis kit (Roche). Firstly, RNA 
samples, reaction buffer, MgCl2, dNTPs, random and oligo dT primers and gelatin 
were put on ice.  250ng of RNA were mixed with distilled water to 7,8 µl and 
denatured at 65°C for 10 minutes using a thermal cycler, then placed on ice for 5 
minutes. The master mix was then prepared as follows: 
 
Volume Component End 
concentration 
2µl  10x reaction buffer 1X 
4µl  25mM MgCl2  5mM 
2µl deoxynucleotide mix 1mM 
1µl  random primers  
1µl  oligo dT primers  
Finally and immediately before adding to the samples: 
1µl  RNase inhibitor 50 units 
0,8µl AMV-reverse transcriptase 20 units 
0,4µl  Gelatin  0,01mg/ml 
 
Afterwards the master mix was added to the RNA samples to a final volume of 20 µl. 
The RNA solution mixture was placed in a thermal cycler and programmed as 
follows: 
10min to 25°C (primer annealing) 
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60min to 40°C (cDNA synthesis) 
5min 99°C (reverse transcriptase inhibition) 
4°C, and finally stored at -20°C 
 
The following day, quantitative PCR was performed using Power Sybr Green master 
mix (Life technologies) as tabulated below. 
 
cDNA dilution  
Volume Component End  
80µl H20   
20µl cDNA (250ng) 2,5ng/µl 
= 100µl     
Primer master mix preparation 
180µl H20   
10µl Forward primer (100µM) 5µM 
10µl Reverse primer (100µM) 5µM 
qPCR master mix  
5µl  Sybr green Master mix 1x 
1µl  
 Primer mix (forward+ 
reverse) 5µM 500nM 
2µl  H20   
= 8µl /sample     
After pipetting 8µl of qPCR master mix to the wells: 
2µl  cDNA (1:5 diluted)  5ng 
= 10µl end volume /well 
 
The samples were then pipetted in a 96 well plate on ice. Before the run, the plates 
were centrifuged shortly at 4°C to avoid air bubbles.  
The following program was employed: 
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Polymerase 
activation PCR 
Melt curve 
CYCLE (40x) Step 
Hold 
Denature Anneal/Extend 
Step and hold 
Temp. 
95°C 95°C 64°C (18s and MCP-1) 95°C 64°C + 0,7°C/min 
until 95°C 
Time 10min 15 sec 1 min 15 sec 1 min  
 
The data obtained on 18S rRNA expression was used for normalisation. 
 
2.2.17. Statistical analysis 
Statistical analyses were carried out using SigmaPlot® 12.0 (Systat Software, SPSS, 
Chicago, IL, USA). For statistical analyses, we performed unpaired Student’s t-test 
when comparing two groups of the same experimental subject. Friedman Repeated 
Measures Analysis of Variance on Rank was used when each group of data from 
experimental mice is to be tested against a control group. Differences were 
accepted to be significant if P < 0.05. Data were presented as standard error of the 
mean (S.E.M). 
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3. RESULTS 
3.1. Collateral arteries change their shape after femoral artery occlusion 
Femoral a r t e r y  ligation resulted in the growth of pre-existing arteriolar 
connections. 21 days after femoral occlusion, two prominent superficial collateral 
arteries displayed a characteristic corkscrew appearance on adductor muscles on 
the occluded side (arrowheads; figure 9 A). On the non-occluded hind limb 
(sham side) pre-existing quiescent collaterals were present (figure 9 B). 
Apart from these superficial collaterals, deep muscular interconnecting arteries 
were made visible by an infusion of red cast material followed by muscle tissue 
maceration (figure 9 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9: Superficial collateral arteries 
21 days after ligation. 
A. Collateral vessels (arrow 
heads) consistently developed 
on the occluded side showing 
the characteristic tortuous 
phenotype. 
B. Sham operated limb showing 
pre-existing quiescent collateral 
arteries (arrows). 
C. A cast model showing the 
presence of deep collateral 
vessels after muscle tissue 
maceration (white arrows) on 
the sham operated limb.  
A B 
C 
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3.2. Mast cells respond to femoral artery ligation with degranulation in the 
vicinity of growing collateral vessels 
Quiescent undegranulated mast cells are present along the collateral arteries already 
before the process of arteriogenesis is initiated (figure 10 A). In the course of 
arteriogenesis, perivascular mast cells degranulate (figure 10B). Mast cells were not 
seen to degranulate within the first two hours after femoral artery ligation. However, 
mast cell degranulation around collateral arteries was progressively increasing with 
time, from no degranulation at 2 hours to 42.5% (± 2.5%) at 12 hours, to 54.25% (± 
3%) at 24 hours and to 59% (± 6%) at 3 days after femoral ligation (figure 10 C). 
Three days after femoral ligation, an average of one degranulated mast cell per 
collateral was observed in histological sections of adductor muscles in the occluded 
limb. However, no degranulation of mast cells was seen in the sham-operated limb 
(figure 10 D).  
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Figure 10; Detection of mast cell degranulation during arteriogenesis 
A and B: Three days after femoral artery ligation mast cells detected in the perivascular 
space of pre-existing collaterals in the non-occluded (sham) side, showed no 
degranulation (arrow; A), while mast cells at the same location in the occluded side 
showed active degranulation (arrow; B). Scale bar; 100µm.  
C: A Bar graph presents the number of degranulated mast cells per collateral in 
percent, 12 hours. 24 hours and 3 days after femoral artery ligation. (*P<0.05, n.s = 
non significant) 
D: Bar graph present the average number of mast cells degranulated per collateral 
from tissue sections of occluded or sham operated m. adductor 3 days after femoral 
artery ligation. (*P<0.05). 
 
3.3. Prevention of perivascular mast cell degranulation impairs arteriogenesis 
Cromolyn is a substance known to block the release of granula by mast cells (figure 
11 A). In this experiment, we compared the time course of recovery of blood flow 
perfusion in the distal hindlimb of controls and of cromolyn treated mice after femoral 
artery ligation with the help of laser Doppler perfusion imaging (LDI). In both saline 
(control) and cromolyn treated groups, the perfusion ratio (right/left) before surgical 
occlusion was approximately one. Immediately after surgery, there was a similar 
decline in the distal hind limb blood flow on the occluded side of both groups (figure 
11 B). However, cromolyn treated mice demonstrated a significantly slower recovery 
of blood flow at day 7, 14 and 21 when compared with control mice (Table I, figure 
11 B). 
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Table I Perfusion ratio (right versus left) of cromolyn treated mice versus controls 
 
 
 
Day 7 R/L: 0.29±0.03  vs. 0.59±0.02, ***P<0.001 treated v.s. saline 
Day 14 R/L: 0.55±0.05  vs. 0.66±0.04, *P<0.05 treated v.s. saline 
Day 21 R/L: 0.56±0.05  vs. 0.76±0.05 *P<0.05 treated v.s. saline. 
 
Next we investigated whether the effect of this reduced perfusion recovery was due 
to a blockage of mast cells around the growing collateral arteries in the cromolyn 
treated mice. We analyzed Giemsa stained histological sections from the adductor 
muscles from the occluded side (figure 11 C) of control and cromolyn treated mice 
and found that the percentage of degranulated mast cells was significantly lower 3 
days after femoral artery occlusion when compared to the control group (figure 11 
D).  
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 Figure 11; Effect of cromolyn on hindlimb perfusion recovery and mast cell 
degranulation. 
A: A sketch diagram showing the function of cromolyn in blocking mast cell 
degranulation. 
B: Line chart showing changes in the rate of hindlimb blood perfusion recovery of 
saline (control) or cromolyn treated mice after femoral artery ligation. The data are 
shown as mean ± SEM, n=6 per group. *P<0.05, **P<0.01, ***P<0.001. 
C: Giemsa stained pictures representing adductor sections of occluded saline 
(control) or cromolyn treated mice 3 days after femoral ligation. In the control, mast 
cells were seen to degranulate, while mainly non-degranulating mast cells were 
seen in sections of cromolyn treated mice (arrows). Scale bar = 100µm. 
*** 
* ** 
** 
C 
D 
A B 
cromolyn 
Stabilized mast cell 
(No degranulation) 
Quiescent 
mast cell 
 
control cromolyn 
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D: Bar graph representing the number of degranulated mast cells in percent per 
collateral in saline (control) or cromolyn treated animals at 3 days post femoral artery 
ligation. Data are shown as mean ± SEM, n=3-4 per group. **P<0.01. 
 
3.4. Effect of stem cell factor and diprotin A on hind limb reperfusion recovery 
following femoral artery ligation.  
 
A group of mice was treated with stem cell factor (SCF), a cytokine which enhances 
mast cell maturation and differentiation, after femoral artery ligation (figure 12 A). 
With laser Doppler measurements I found a significantly increased rate of perfusion 
recovery of the hind limb on the occluded side at day 7 when compared to saline 
(control) treated mice (R/L ratio, 0.73±0.02 vs. 0.56±0.02, *P<0.05 SCF vs. control). 
However, 14 and 21 days after femoral ligation the perfusion had recovered virtually 
to the same extent in each of the two groups (figure 12 B). In a similar experiment, 
mice were treated with diprotin A, which increase the serum level of SDF-1α through 
inhibition of DPPIV enzyme (figure 12 C), thereby enhance mast cell recruitment (c-
Kit+; figure 12 D). The increase of SDF-1α was significant in the collaterals of 
diprotin A compared to control (figure 12 E). However, the level of SDF-1α in the 
serum was slightly higher in diprotin A treated mice, albeit not significant (figure 12 
F). As a result, the rate of perfusion recovery had accelerated at days 7 and 14 in 
diprotin A treated mice with respect to controls (table II; figure 12 G).  
Table II Diprotin A treated versus control mice 
 
Day 7 R/L: 0.76±0.04 vs. 0.56±0.02 **P<0.01 diprotin A v.s. control 
Day 14 R/L: 0.85±0.05 vs. 0.66±0.04 *P<0.05 diprotin A v.s. control 
Day 21 R/L: 0.84±0.04 vs. 0.76±0.05 Not significant 
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Figure 12; Improved arteriogenic responce in hindlimbs of SCF and diprotin A 
treated mice.  
A: Sketch diagram showing SCF mode of action toward mast cells.  
B: Line charts showing laser Doppler quantitave analyses of perfusion measurement 
(occluded/sham) in saline (control) or SCF treated mice. *P<0.05. 
C: Sketch diagram showing diprotin A mode of action toward mast cells. inSDF-1α 
(inactive stroma-cell-derived factor 1-α), aSDF-1α (active stroma-cell-derived factor 
1-α). 
D. Bar graph displaying the results of mast cell (c-Kit+) counts by flow cytometry in 
the adductors of saline (control) or diprotin A treated mice 24 hours after femoral 
artery ligation 
E. Quantification of collateral SDF-1α levels (pg/mg) by means of ELISA of control 
with ligation (control w lig) or ligation and diprotin A treatment (dipA w lig) 24 hours 
after femoral artery ligation. 
F. Bar graph showing ELISA results on quantification of serum SDF-1α levels 
(pg/mg) of control (saline treated) mice without ligation (control w/o lig), control with 
ligation (w lig) or ligation and diprotin A treatment (dipA w lig) 24 hours after the 
surgery 
G: Laser Doppler quantitative analyses of perfusion measurement (occlude/sham) in 
saline (control) or diprotin A treated mice. **P<0.01. 
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3.5. Mast cell degranulation with the help of compound 48/80 accelerates hind 
limb perfusion recovery 
The recovery of hind limb blood perfusion after femoral artery ligation was further 
studied in mice treated with compound (C) 48/80 and compared with saline treated 
control mice. To determine the progress of collateral artery growth, blood flow was 
measured before, directly after surgery and then 3 days, 7 days, 14 days and 21 
days after surgery with laser Doppler imaging (LDI). With respect to control values 
the perfusion ratio of C 48/80 treated mice recovered significantly faster at day 7 and 
14 (Table III; figure 13 A).  
 
 
 
 
 
 
 
Table III C 48/80 treated versus control mice 
 
Day 7 R/L: 0.79±0.03  vs. 0.56±0.02, **P<0.01 treated v.s. saline 
Day 14 R/L: 0.85±0.04  vs. 0.66±0.04, *P<0.05 treated v.s. saline 
Day 21 R/L: 0.84±0.06  vs. 0.76±0.05 Non-significant. 
 
In order to examine whether the three substances which accelerate perfusion 
recovery (C 48/80, diprotin A and SCF), have additive effects, we treated one group 
of mice with C 48/80 + diprotin A and another group with C 48/80 + diprotin A + SCF. 
In the group of mice treated with C 48/80 + diprotin A we found a significantly faster 
blood flow recovery with respect to controls already at 3 day after surgery. The 
perfusion remained consistently better until day 21 (table IV; figure 13 A). Even 
though the group with a double treatment (C 48/80 + diprotin A) and the group with a 
triple treatment (C 48/80 + diprotin A + SCF) exhibited additive effects, the results 
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between these double and triple treated groups were not significantly different from 
each other (figure 13 A). Interestingly, a statistically significant recovery in blood flow 
was already detected at day 3 in mice  treated with C 48/80 + diprotin A in contrast 
to mice treated exclusively with C 48/80 or with diprotin A.  
Table IV C 48/80 + diprotin A treated versus control mice 
 
Day 3 R/L: 0.42±0.06  vs. 0.23±0.02, *P<0.05 treated v.s. saline 
Day 7 R/L: 0.84±0.06  vs. 0.56±0.02, ***P<0.001 treated v.s. saline 
Day 14 R/L: 0.94±0.06  vs. 0.66±0.04, **P<0.01 treated v.s. saline 
Day 21 R/L: 0.92±0.05  vs. 0.76±0.05 *P<0.05 treated v.s. saline. 
 
This accelerated recovery rate due to diprotin A treatment could have resulted 
exclusively from a contribution of mast cells or from a contribution of monocytes 
(which expresses the receptor for SDF-1α i.e. CXCR-4). Alternatively, it could have 
resulted from a contribution of both cell types. In order to find out, we blocked the 
degranulation of mast cells by the application of cromolyn either in the presence or 
in the absence of diprotin A. The results of this experiment (figure 13 B) 
demonstrated that blocking mast cell degranulation significantly reduced perfusion 
recovery after femoral artery ligation with respect to controls. In the presence of 
cromolyn the rate of perfusion recovery was reduced with respect to controls, 
regardless of a single cromolyn treatment or a combined cromolyn plus Diprotin A 
treatment (figure 13 B).  
As shown above, mice treated with a combination of C 48/80 + diprotin A, exhibited a 
significant increase in perfusion recovery of their hind limb perfusion already 3 days 
after femoral artery ligation. To find out at what time the increase in blood flow had 
started we investigate the blood flow within the first 48 hours after femoral artery 
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ligation. In fact, we found a significantly increased perfusion already 6 hours after 
surgery (figure 13 C). This increase was persistent up to 48 hours post surgery, albeit 
it was not significant at 12 and at 24 hours post surgery (figure 13 C).   
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* - Diprotin A vs control 
& - Cromolyn vs control 
# - Cromolyn+dipA vs. cromolyn 
 
 
 
Fig.13. LDI perfusion measurements after influencing mast cell function.  
A: Line charts of laser Doppler results showing the perfusion ratio (occluded/sham) 
in mice treated with compound 48/80, diprotin A (dipA), a combination of C 48/80 + 
diprotin A, and C 48/80 + diprotin A + SCF versus control.  *P<0.05, **P<0.01, 
***P<0.001. $P<0.05, $$P<0.01, $$$P<0.001. #P<0.05, ##P<0.01. &P<0.05, &&P<0.01. 
ɸP<0.05. 
B: Laser Doppler results displaying the perfusion ratio (occluded/sham) of mice 
treated with diprotin A, cromolyn, or a combination of diprotin A + cromolyn versus 
control mice. *P<0.05, **P<0.01. &P<0.05, &&P<0.01, &&&P<0.001.  
C: Quantification of perfusion ratio (occluded/sham) at 6, 12, 24 and 48 hours post 
ligation of combined C 48/80 + diprotin A treated mice versus control. (*P<0.05). 
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3.6. Mast cell degranulation promotes vascular remodeling through increased 
MMP enzymatic activity in collaterals 
 
Given that an increased activity of matrix metalloproteinase (MMP) is known to 
promote arteriogenesis (Ota et al., 2009), we investigated the activity of MMP in 
collateral arteries 24 hours after femoral artery ligation of animals treated with stem 
cell factor (SCF) or with C48/80 + diprotin A and compared the results with saline 
treated animals (control). MMP activity had increased significantly in C48/80 + 
diprotin A treated mice by a factor of 2.2 with respect to controls (figure 14). We also 
observed a non-significant increased MMP activity in SCF treated mice versus 
control.   
 
 
 
Fig. 14; Characterisation of MMPs activity in mouse collateral arteries 24 hours after 
femoral artery ligation. 
Bar graph showing quantification of the enzymatic activity of MMPs expressed as 
mean optical density (mOD) measured by the intensity of the emitted fluorescence 
after 1 hour of incubation of homogenised occluded collaterals from saline (control), 
n.s 
n.s 
* 
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SCF or C48/80 + diprotin A treated mice with MMP substrate solution. (Mean ± SEM, 
*P<0.05). 
 
 
3.7. Protein array analysis showed elevated serum levels of PDGF-BB, 
angiopoietin-1 and MMP-3 and 9  
It had been proposed that degranulating mast cells release a number of 
cytokines/chemokines and growth factors; in addition they indirectly activate MMP 
(Gruber et al., 1989). Therefore, we performed in a cytokine assay approach a 
quantitative measurement of cytokines/chemokines in mice serum to identify specific 
proteins that are associated with collateral artery growth. In order to analyse the 
expression profile of arteriogenesis-related proteins in our experimental animals, 
blood was isolated from the three groups of mice (i.e. saline treated, controls without 
ligation; saline treated controls with ligation and of mice treated with a combination of 
C48/80 + Diprotin A). The data demonstrate a strong increase in angiopoietin 1 (by a 
factor of 9) and in the growth factor (PDGF-BB; by a factor of 5) in mice treated with 
a combination of C48/80 + diprotin A (table V; figure 15).  
Table V. Mean pixel density in C48/80 + diprotin A vs. control 
Serum protein C48/80 + diprotin A versus 
control without ligation 
C48/80 + diprotin A versus 
control with ligation 
Angiopoietin 1 32418.5 vs. 3800.5 32418.5 vs. 3535 
PDGF-BB 13031 vs. 2720 13031 vs. 3064.5 
 
In addition, we observed a small increase in mean pixel density of MMP-3 and of 
MMP-9 proteins (figure 15). 
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Fig.15. Serum protein array 
Quantification of proteomic analysis of mouse serum of control without ligation, 
control with ligation or combination of C48/80 + diprotin A 24 hours after femoral 
artery ligation (fal).  
3.8. The extent of mast cell degranulation covaries with the progress of 
vascular cell proliferation 
In order to identify proliferating cells in growing collateral arteries, we used the 
proliferation marker ki67 (figure 16). Three days after femoral artery ligation, nuclei of 
proliferating collateral vascular cells were stained with ki67. 
With respect to controls, cells showing the Ki67 marker were more numerous in mice 
treated with C48/80 + diprotin A (figure 16 E). However, this difference was 
statistically not significant. In cromolyn treated and in cromolyn + diprotin A treated 
mice the number of Ki67 positive cells was smaller than in controls or in 
C48/80+diprotinA treated mice (figure 16 E). The differences between mice treated 
with cromolyn or with cromolyn + diprotin A and mice treated with C48/80 + diprotin A 
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were statistically significant (figure 16 E), whereas no significant differences were 
seen with respect to controls (table VI; figure 16 E).    
Table VI. The number of Ki67+cell/collateral in experimental and control mice. 
C48/80 + dip A vs. cromolyn 2.1 ± 0.4 vs. 1.16 ± 0.3 *P<0.05 
C48/80 + dip A vs. cromolyn + dip A 2.1 ± 0.4 v.s. 1.08 ± 0.3 *  *P<0.05 
C48/80 + dip A vs. control 2.1 ± 0.4 v.s. 1.6 ± 0.4 Non-significant 
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Fig.16. Quantification of Ki67 staining in mice collateral arteries.  
Imunohistochemical detection of Ki67 (red-brown cell nuclei) was performed on mice 
adductor sections from saline (control) (A), C48/80 + diprotin A (B), cromolyn (C), or 
cromolyn + diprotin A (D) treated animals. Black arrows point to Ki67+ nuclei in 
endothelial cells (arrows) and smooth muscle cells (arrow head). Scale bar = 100µm.  
E: Ki67+ nuclei were quantified per collateral in animal treated with C48/80 + diprotin 
A, cromolyn + diprotin A or cromolyn versus control mice (*P<0.05). 
3.9. Degranulation of mast cells increases the expression of MCP-1 in 
collaterals 
An increased expression of monocyte chemoattractant protein (MCP)-1 during 
arteriogenesis is well described (Ito et al., 1997). It is so far unknown however, 
whether mast cells can influence the expression of MCP-1. To find out, we isolated 
collaterals 12 hours after femoral artery ligation from the occluded side and from the 
sham side of control mice (saline treated), of mice treated with C 48/80 and of mice 
treated with a combination of C 48/80 + diprotin A treated mice. We analyzed these 
collaterals with quantitative real time-polymerase chain reaction (qRT-PCR) to 
investigate mRNA levels.  With respect to control mice was the expression of MCP-1 
in collaterals of mice that were treated with a combination of C 48/80 + diprotin A 
* 
* 
* n.s 
n.s 
n.s 
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significantly increased (by a factor of 2.7). In mice that were treated with C 48/80 the 
expression of MCP-1 was not significantly increased (by a factor of 2.0; figure 17 A). 
Interestingly, the expression of MCP-1 on the sham-operated side was very small 
when compared to the occluded side of controls or of C 48/80 treated mice. Since 
mast cells degranulate mainly on the occluded side (see figure 10), the large 
difference in the expression of MCP-1 in collaterals on the sham operated and on the 
occluded side demonstrates the importance of mast cell degranulation for the 
expression of MCP-1.   
This increase in the MCP-1 expression in collaterals could have materialized in a 
corresponding increase in the level of MCP-1 protein in mice treated with C 48/80 + 
diprotin A. Therefore, we evaluated the MCP-1 protein level of the collaterals 24 
hours after femoral artery ligation.  As a result, the MCP-1 protein in the collaterals of 
the occluded had increased significantly (a factor of 3.4; figure 17 B).  However, at 
the same time the plasma concentrations of MCP-1 in C 48/80 + diprotin A treated 
mice and in controls were similar (figure 17 C).  
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Figure 17. Bar graphs showing relative collateral MCP-1 mRNA expression and m. 
adductor and plasma MCP-1 protein levels:  
A. Bar graph representing the mRNA level of MCP1 in collaterals of saline (control), 
C 48/80 or C 48/80 + diprotin A treated animals as analyzed by qRT-PCR 12 
hours after femoral artery occlusion (black bars) or sham (grey bars). *P<0.05, 
**P<0.01 
B. Quantitative analysis of collaterals MCP-1 protein levels by means of ELISA in 
saline (control) or combined C 48/80 + diprotin A treated mice 24 hours after 
femoral artery ligation. *P<0.05. 
C. A histogram showing plasma MCP-1 protein level 24 hours after femoral artery 
ligation in saline (control) or C 48/80 + diprotin A treated animals. 
 
 
3.10. Inhibition of mast cell degranulation reduces the release of TNF-α and 
lowers its plasma level. 
Tumor necrosis factor (TNF)-α, is a cytokine involved in inflammation (Bradley, 
2008). With the help of ELISA, we could not detect any measurable amount of 
TNF-α  in the plasma of control mice without femoral ligation. In control mice with 
femoral artery ligation, we found 1.47 pg/mg protein of plasma TNF-α. However, 
after mast cell degranulation had been inhibited by a treatment with cromolyn,  
mice with a ligation of the femoral artery exhibited a significant reduction in their 
plasma TNF-α protein levels with respect to controls with ligation (1.47 ± 0.2 v.s. 
n.s 
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0.36 ± 0.24 control with ligation versus cromolyn with ligation treated mice, 
*P<0.05) (figure 18).  
 
 
 
 
Figure 18: Plasma TNF-α levels 
Bar graph showing ELISA results on quantification of plasma TNF-α levels (pg/mg) 
of control (saline treated) mice without ligation (control w/o lig), control with ligation 
(w lig) or ligation and cromolyn treatment (cromolyn w lig) 24 hours after the surgery 
(*P<0.05) 
 
3.11. Mast cell degranulation recruits leukocytes  
Leukocytes, especially monocytes are known to be recruited and to play a central 
role in the development of collateral arteries during the early phase of arteriogenesis 
from 24 hours to 3 days (Arras et al., 1998). As a first step, we assessed the number 
of leukocytes in the vicinity of growing collaterals three days after femoral artery 
ligation. Leukocytes were stained with CD45 antibodies (figure 19 A). In mice treated 
with C 48/80 + diprotin A we found significantly more perivascular leukocytes (on an 
average 8 CD45+ cells, i.e. leukocytes, per collateral) than in saline treated control 
animals (on average 2 leukocytes). On the other hand, the induction of leukocyte 
n.s 
* * 
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recruitment was abrogated by the application of the mast cell stabilizer cromolyn 
(figure 19 B).  We then assessed whether the recruitment of leukocytes provoked by 
the application of diprotin A can be suppressed by a concomitant application of the 
mast cell stabilizer cromolyn. As a result, the number of perivascular leukocytes in 
cromolyn + diprotin A treated mice was significantly smaller than in mice treated with 
C 48/80 + diprotin A, but with respect to cromolyn mice treated mice the number of 
leukocytes in cromolyn + diprotin A treated mice was slightly increased (figure 19 B).    
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Figure. 19. Histological quantification of perivascular leukocytes 
A: Representative images of immunohistochemical staining of leukocytes (CD45+, 
brown cells) in a combined C 48/80 + diprotoin A treated group in comparison to 
saline (control), cromolyn, or combination of cromolyn + diprotin A (dipA) treated 
mice. Scale bar = 100µm.  
B; Bar graph showing the average number of leukocytes per collateral 3 days after 
femoral artery ligation in control, cromolyn, combination of cromolyn + diprotin A, or 
combination of C 48/80 + diprotin A treated animals. (*P<0.05, ***P<0.001). 
 
To define the subpopulation of the perivascular leukocytes we investigated the 
differential cell population in the adductor muscles and in the blood by flow 
cytometry. The flow cytometric analysis of freshly isolated adductor muscle tissue 
from the occluded hindlimb 24 hours after femoral ligation revealed a significant 
*** 
*** 
*** 
* 
B 
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increase in the number of neutrophils and of macrophages (Table VII; figure 20 A-C). 
In addition, I analyzed the blood of the same two groups of mice 24 hours post 
femoral ligation. Flow cytometry analysis revealed an increased number of 
neutrophils (Gr-1+ CD115-), Macrophages and monocytes (CD 115+), and T cell 
(CD4+ and CD8+) (table VIII; figure 20 D-F).  
 
Table VII. Leukocyte subpopulation in adductor muscles 24 hours after ligation.  
cell marker C 48/80 + dipA vs. control Statistical significance 
Gr-1+ CD115- 8.4% ± 4.0% vs. 0.36% ± 0.37% *P<0.05 
F4/80+ 12.2% ± 2.1% vs. 1.65% ± 0.81% **P<0.01 
 
 
 
 
 
Table VIII. Leukocyte subpopulation in the blood 24 hours after ligation.  
cell marker C 48/80 + dipA vs. control Statistical significance 
Gr-1+ CD115- 22.5% ± 2.6% vs. 0.91% ± 1.0% **p<0.01 
CD115+ 4.6% ± 0.95% vs. 3.3% ± 3.2% Non-significant 
CD4+ 3.5% ± 0.9% vs. 0.4% ± 0.4% *P<0.05 
CD8+ 2.4% ± 0.6% vs. 0.22% ± 0.18% *P<0.05 
In addition, we identified the subpopulations of leukocytes and compared their 
numbers three days after femoral artery ligation in freshly isolated adductor muscles 
from the occluded limbs of C 48/80 + diprotin A treated and of control mice. In the 
group of mice that received a combined C 48/80 + diprotin A treatment the numbers 
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of macrophages were significantly increased (table IX; figure 20 G-I). In the same two 
groups of mice, we assessed the pattern of leukocyte subpopulations in the blood 3 
days post femoral ligation. Flow cytometric analysis showed no differences in the 
numbers of these cell subpopulations between mice treated with C 48/80 + diprotin A 
and control mice (figure 20 J-L).  
Table IX. Leukocyte subpopulation in adductor muscles 3 days after femoral artery 
ligation.  
cell marker C 48/80 + dipA vs. control Statistical significance 
Gr-1+ CD115- 3.6% ± 1.9% vs. 0.06% ± 0.01% Non-significant 
F4/80+ 5.36% ± 1.0% vs. 0.26% ± 0.01% **P<0.05 
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(I)  C48/80+dipA m.adductor 3 days post ligation 
(K)  Control blood samples 3 days post lig 
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Figure 20: 
Vertical bar charts and FACS images of m.adductor and blood samples 24 hours and 
3 days post ligation. 
Vertical bar chart showing the results of cell counts by flow cytometry in the 
adductors (A) and blood (D) of saline (control) and combined C 48/80 + Dip A treated 
mice 24 hours after femoral artery ligation (fal). Representative images of flow 
cytometry analyses showing different cell population in the adductors of saline 
(control) (B) and combined C 48/80 + diprotin A (C) treated mice, and in the blood of 
control (E) and combined C 48/80 + diprotin A (F) 24 hours post ligation.  
Bar graph displaying the results of cell counts by flow cytometry in the adductors (G) 
and blood (J) of saline (control) and combined C 48/80 + Dip A treated mice 3 days 
after femoral artery ligation (fal). Representative images of flow cytometry  showing 
different cell population in the adductors of control (H) and combined C 48/80 + 
diprotin A (I) treated mice, and in the blood of control (K) and combined C 48/80 + 
diprotin A (L) 24 hours post ligation. (*P<0.05). 
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3.12. Treatment of mice with C 48/80 + diprotin A results in an increased 
collateral vessel diameter  
To investigate whether the increased blood flow in the distal hind limb results from 
outward vascular remodeling, we measured the inner diameter of collateral arteries in 
the adductor muscle 3 and 7 days after femoral artery ligation. 3 days after femoral 
artery ligation we found an increase in the luminal diameter by a factor of 1.3 in 
C48/80 + Dip A treated mice with respect to control mice (figure 21 A). Seven days 
after femoral artery ligation, the collateral diameter in C 48/80 + diprotin A treated 
mice was significantly increased by a factor of 1.7 with respect to control mice (figure 
21 B).  This increase in the diameter of collateral arteries explains the increase in the 
blood flow in the distal hind limb and can be expected to have a beneficial effect on 
the preservation of muscular tissue, e.g. the gastrocnemius muscle. 
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Fig.21. Quantification of collateral artery enlargement 
Bar graphs showing the quantification of luminal diameter (µm) at day 3 (A), and day 
7 (B) after femoral artery ligation in saline (control) or C 48/80 + diprotin A treated 
mice. (*P<0.05). 
C: Representative pictures of hematoxylin-and-eosin (H&E) staining from adductor 
tissue sections of mice in ligated hind limbs at day 3 and 7 post femoral ligation in 
control or C 48/80 + Diprotin A treated mice. Scale bars = 100µm. 
 
 
4.13. Improved perfusion reduces distal tissue ischemic damage  
Paraffin fixed tissue sections taken 3 days after femoral artery ligation were stained 
with haematoxylin and eosin. Histological analyses of the m. gastrocnemius three 
days after surgery revealed more pronounced fibrosis in saline treated control mice 
than in mice treated with a combination of C 48/80 + diprotin A. In the latter group of 
animals, almost no fibrosis was detected in the calf muscles (figure 22 A-F). Sections 
of the calf muscles were in addition assessed and quantified for leukocyte infiltration 
(CD45+ cells). Consistent with the large extent of tissue fibrosis seen in control mice, 
there was also an increase in the number of leukocytes in the tissues from control 
mice when compared to C 48/80 + diprotin A treated mice (CD45+ cells/mm2: 208 ± 
33 in control mice vs. 18 ± 16 in C 48/80 + diprotin A treated mice; ***P<0.001; figure 
22 G-I). Furthermore, the capillary endothelial cells in the gastrocnemius muscle 
were investigated by CD31 antibody staining. Our results revealed a significant 
increased ratio of capillaries per muscle fibre in the ligated hind limb of control group 
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when compared to C 48/80 + diprotin A treated mice (CD31+ cells/muscle fibre: 2.48 
± 0.2 in C 48/80 + diprotin A treated mice vs. 1.1 ± 0.1 in control mice; ***P<0.001; 
figure 22 J). Interestingly, the ratio of capillaries per fibre in the gastrocnemius 
muscle of a ligated hind limb treated with C 48/80 + diprotin A mice were equivalent 
with the unligated (sham) side as well as that of unligated control (figure 22 J-L). 
Furthermore, we investigated whether the absence of tissue fibrosis seen in C 48/80 
+ diprotin A treated mice was related to mast cell degranulation in the gastrocnemius 
muscle. As a result, neither femoral artery ligation nor local application of C 48/80 in 
the upper leg resulted in mast cell degranulation in the gastrocnemius muscle (figure. 
22 M). This implies that tissue preservation in the gastrocnemius muscle did not 
result from a local mast cell degranulation in this muscle but was rather the result of 
arteriogenesis in femoral collaterals. 
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Fig. 22: Histological analysis of the m. gastrocnemius.  
Quantification of fibrosis in the tissue sections of the gastrocnemius of saline (control) 
or combined C 48/80 + diprotin A treated mice (A) (*P ≤ 0.05). Representative 
pictures of H&E stained m. gastrocnemius of control (B) or C 48/80 + diprotin A (C) 
treated mice (scale bar = 100µm). (D) Shows the m. gastrocnemius of a sham 
operated mouse and (E) and (F) present magnification of (B) and (C), respectively. 
(scale bar = 100µm). 
Quantification of leukocyte (CD45+ cells; stained brown, arrows) in m. gastrocnemius 
of control mice or C48/80 + diprotin A treated mice (G) (***P ≤ 0.001). Representative 
pictures of CD45 positive cells in control (H) or C 48/80 + diprotin A treated mice (I) 
(scale bar = 100µm). 
J L K 
*** 
*** 
*** 
n.s 
M 
80 
 
Bar chart showing the quantification of capillaries (CD31+ cells) per muscle fibre, (J) 
in the m. gastrocnemius of saline (control) or C 48/80 + diprotin A treated mice (**P ≤ 
0.01). Representative pictures of CD31 antibody staining (stained brown, arrows) in 
saline (control) (K) or C 48/80 + diprotin A treated mice (L) (scale bar = 100µm).  
Representative Giemsa staining showing (M) mast cells and their magnification (top 
right) in the m. gastrocnemius of mice in the saline treated (control) sham, control 
with occlusion and in the occluded C 48/80+ diprotin A treated mice three days after 
femoral artery ligation. (Scale bar 100µm). 
 
3.14. Mechanism of mast cell degranulation during untreated arteriogenesis   
 
As shown above, mast cells respond to femoral artery ligation with a degranulation 
(figure 10 E). This reaction is independent of the presence or the absence of a 
treatment. It is therefore of interest to understand the mechanisms that underlie this 
response. A number of candidates could be of importance in the induction of mast 
cell degranulation, such as the neuropeptide substance P or neutrophils.  
In order to prevent substance P from an induction of mast cell degranulation, we 
administered RP-67580, which inhibits the release of substance P (Malcangio and 
Bowery, 1994). Laser Doppler imaging showed that inhibition of substance P had no 
effect in hind limb perfusion recovery rate (figure 23 A). Next we investigated whether 
neutrophils mediate the degranulation of mast cells. To that end we applied Ly6G 
(1A8) antibodies, which depleted circulating neutrophils (Daley et al., 2008) by 70% 
within 2 days after their application (figure 23 B). Treatment of wild type mice with 
1A8 resulted in a significantly slower perfusion recovery 7 days after femoral artery 
occlusion (0.49±0.03) than in controls (0.71±0.07; *p<0.05; figure 23 C). This slower 
recovery rate could have resulted from a reduced number of degranulated mast cells. 
A histological analysis of Giemsa stained adductor muscle sections from mice treated 
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with 1A8 antibodies revealed in fact a significantly decreased mast cell degranulation 
24 hours after femoral artery ligation (figure 23 D).  
Since neutrophils are suggested to be the first cells recruited in the process of 
arteriogenesis (Behm et al., 2008) we investigated our working hypothesis, according 
to which neutrophils are involved in the degranulation of mast cells. More precisely, 
Nox 2 (NADPH oxidase) a major source of reactive oxygen species (ROS) in 
neutrophils is released by neutrophils upon platelets/neutrophils interaction 
(Vanichakarn et al., 2008). The release of ROS in turn degranulates mast cells.     
To investigate this hypothesis we used Nox-2 null (Nox2-/-) mice. In Nox2-/- mice 
femoral artery ligation was induced and the adductor muscle was analyzed 
histologically to quantify mast cell degranulation 24 hours and 3 days after surgery. 
We found that the extent of mast cell degranulation in Nox 2-/- deficient mice was 
significantly reduced 24 hours as well as 3 days after a ligation of the femoral artery 
with respect to control mice (figure 23 D and E).  
Furthermore, I used the NADPH oxidase inhibitor (apocynine) or a ROS scavenger 
(N-acetylcystein) to block ROS. In both experiments histological analysis revealed a 
significant reduction in the number of degranulated mast cell upon femoral artery 
ligation (figure 23 D). These results indicate that a reduction in the production of ROS 
results in a smaller number of degranulated mast cells.  
A similar reduction in the production of ROS was observed by (Evangelista et al., 
2005) after the inhibition of the interaction between platelets and neutrophils.  
Therefore we investigated the degranulation of mast cells in histological sections of 
adductor muscles from GPIbα-/- mice (a platelet adhesion receptor) 3 days after 
femoral artery ligation. We found a significant reduction of mast cell degranulation in 
GPIbα-/- mice when compared to control mice (figure 23 E). Furthermore, we 
82 
 
investigated adductor muscle sections from urokinase plasminogen activator (uPA-/-) 
mice. These mice are deficient proteolytic activity of plasminogen to plasmin. In this 
experiment they revealed a significant reduction of mast cell degranulation when 
compared to control mice (figure 23 D).  These results imply that mast cell 
degranulation during untreated arteriogenesis is mediated by neutrophil derived ROS 
production in the vicinity of collateral arteries. This process is dependent on 
platelet/neutrophil interaction mediated by the platelet receptor GP1bα as well as 
uPA dependent extravasation of neutrophils. 
 
 
 
 
 
 
 
A 
B C 
83 
 
        
 
  
 
 
** 
* 
** 
* 
D 
E 
** 
** 
*** 
* 
*** *** 
* 
α 
84 
 
 
Figure 23: Mast cell degranulation during un-influenced arteriogenesis. 
Quantification of perfusion recovery ratio (occluded/sham) of mice treated with 
substance P release inhibitor (RP-67580) versus saline treated (control) (A).  
Bar graph displaying the effectiveness of a neutrophil depletion substance (1A8) in 
blood (B) (**P<0.01). Laser Doppler measurements shows the perfusion ratio of 1A8 
treated mice in comparison to saline treated (control) (C) (*P<0.05). 
D: A vertical bar chart of saline (control), cromolyn, 1A8, NAC (N-acetylcystein) and 
apocynin treated mice and uPA-/- and Nox2-/- mice showing the percentage of mast 
cell degranulated around growing collaterals 24 hours after femoral artery ligation 
(*P<0.05, **P<0.01, ***P<0.001).  
E: Bar chart showing the percent of mast cell degranulated in saline (control) and 
cromolyn treated mice, as well as Nox2-/- and GPIbα-/- mice 3 days after femoral 
artery ligation (fal) (E) (*P<0.05, **P<0.01, ***P<0.001). 
 
 
 
 
 
 
 
 
 
 
4. DISCUSSIONS 
The occlusion of an artery is followed by a redirection of the blood flow through pre-
existing arterial collaterals. Due to outward remodelling, the diameter of these 
collaterals enlarges and their tortuous shape becomes more and more corkscrew-
like.  This process of arterial growth is assumed to be initiated by increased 
mechanical forces such as shear stress and circumferential wall stress (Yang et al., 
2013). Thereby, the endothelium becomes activated, recruiting leukocytes and 
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endothelial and smooth muscle cells of pre-existing arterial collaterals proliferate. The 
enlargement of these pre-existing arterial collaterals is strongly dependent on the 
accumulation of perivascular leukocytes (especially monocytes), as a source of 
important growth factors and cytokines. In fact, Hoefer et al. (2005) showed that 
monocytes and macrophages locally supply growth factors and cytokines that 
promote collateral artery growth.  
4.1 Mast cells degranulate in response to arterial occlusion 
In addition to pericytes, mast cells are present in the vicinity of pre-existing arterial 
collaterals as well. Suggestive evidence indicated that mast cells may also be 
involved in tissue remodelling and in arteriogenesis. Mast cells accumulate in the 
adventitia of growing collaterals (Schaper and Scholz, 2003) and they are important 
immune effector and modulatory cells that are involved in tissue remodelling (Saito, 
2005). In normal physiological state mast cells remain essentially quiescent. But 
activation of mast cells results in the release of a variety of mediators including 
important growth factors and enzymes, a process known as degranulation. 
Therefore, a prerequisite for a possible functional contribution of mast cells in 
arteriogenesis is degranulation in response to arterial occlusion. However, so far no 
reports were available concerning degranulation of mast cells in response to arterial 
occlusion. Therefore, we analysed the reaction of mast cells in our mouse model and 
observed in our histological investigation a progressively increased mast cell 
degranulation within the first 3 days after femoral artery ligation (figure 10 E). This 
activation of mast cells was restricted to the perivascular vicinity of pre-existing 
collaterals in the region of the occluded artery. Mast cells along corresponding 
collaterals in the non-operated limb were essentially stable and non-degranulating 
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(figure 10 D). Interestingly, no degranulation of mast cells was observed on the 
operated side in the lower limb (m.gastrocnemius), even when ischemia and tissue 
necrosis were severe (figure 23 E). This observation implies that ischemia and its 
consequences are not relevant signals for the activation of mast cells.   
4.2. Reduced mast cell degranulation slows down the speed of arteriogenesis  
Given that mast cells degranulate in response to the occlusion of an artery, we 
investigated a possible functional contribution of mast cells by the application of 
cromolyn, a substance which is known to stabilize mast cells by inhibiting their 
degranulation (Brogden et al., 1974). Our histological analysis revealed a significantly 
decreased percentage of degranulated mast cells around the growing collaterals in 
mice treated with cromolyn (figure 11 C and D). We analysed the functional 
consequences of a stabilization of mast cells with cromolyn for the blood flow 
reperfusion after femoral artery ligation with a laser Doppler imaging technique. As a 
result, the rate of recovery of the blood flow distal to the femoral artery ligation was 
slowed down for 21 days after the administration of cromolyn (figure 11 A). This 
result implies that mast cell degranulation in response to femoral artery occlusion is 
not just an event that parallels arteriogenesis. Rather, a reduced rate of release of 
granula by mast cells has a negative effect upon the speed of arteriogenesis and 
upon the rate of blood flow recovery. 
 
4.3. Enhanced mast cell degranulation accelerates the rate of blood flow recovery 
Compound 48/80, a mixture of polymers formed after the condensation of p-
methoxyphenethylamine with formaldehyde, activates the secretory process of mast 
cells (Nakamura and Ui, 1985) through a direct activation of G-membrane proteins 
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(Mousli et al., 1990). With the application of C 48/80 we could further test our working 
hypothesis, according to which mast cell degranulation is an important factor for the 
progress of arteriogenesis in general and an enhanced rate of mast cell 
degranulation should improve the speed of arteriogenesis and the rate of blood flow 
recovery in particular. In fact, the application of C 48/80 increased the rate of hind 
limb blood flow reperfusion significantly at days 7 and 14 with respect to saline 
treated control animals (figure 13 C).  
 
4.4 Enhanced recruitment of mast cells and of other leukocytes accelerates the rate 
of blood flow recovery   
Diprotin A (Ile-Pro-Ile tripeptide) is a dipeptidyl aminopeptidase IV (DPP IV / CD26) 
inhibitor, an ectoenzyme protease, which cleaves the potent chemoattractant 
molecule SDF-1α in the serum (Christopherson et al., 2004, Zaruba et al., 2009). 
Mice treated with diprotin A showed a significantly faster blood flow recovery than 
controls. The pattern of blood flow recovery was similar to that of mice treated with 
C48/80 (figure 12 B). Given that diprotin A increases the recruitment of stem cells 
from the bone marrow including immature mast cells and monocytes through an 
enhanced SDF-1α level (Christopherson et al., 2004, Vagima et al., 2011). In our 
experiments we found that this reaction is also present in the context of growing 
collateral arteries (figure 12 D). Therefore, more bone marrow stem cells of leukocyte 
lineage differentiate and mature around the growing vessel and release more 
chemokines and growth factors, which are necessary for arteriogenesis.  
It has previously been shown that those subtypes of stem cells which differentiate 
into endothelial cells and smooth muscle cells do not play a role in arteriogenesis 
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(Heil et al., 2004). However, those perivascular mast cells, which possess c-kit 
receptor for stem cell factor (SCF;(Costa et al., 1996) could be important for 
arteriogenesis. Therefore, we investigated the effect of SCF for arteriogenesis. SCF 
is a dimeric molecule, which binds and activates receptor tyrosine kinase c-kit. SCF 
has been associated with mast cell survival, migration, differentiation and 
proliferation (Galli et al., 1993). Application of SCF increased the rate of blood flow 
reperfusion only at day 7 and thereafter blood flow returned to normal control values 
(figure 12 A). The observed increased rate of recovery at day 7 could be explained 
by an increase in the total number of mast cells in the perivascular region of collateral 
vessels during the process of arteriogenesis.  
 
4.5. A combined increase in degranulation and recruitment has additive effects 
A combined treatment of mice with C 48/80 plus diprotin A was expected to exhibit a 
particularly strong effect on growing collateral arteries, given that C 48/80 enhances 
the degranulation of mast cells and that diprotin A enhances the recruitment of mast 
cells as well as of leukocytes. In fact, the recovery of blood flow in mice treated 
simultaneously with C 48/80 and diprotin A was significantly accelerated with respect 
to control mice already on day 3 after ligation of the femoral artery. This positive 
effect persisted until day 21. The increased rate of reperfusion at day 3 was not only 
significant with respect to the rate of reperfusion in controls, but also with respect to 
the rate of reperfusion in mice that had been treated either with C 48/80 or with 
Diprotin A alone (figure 13 D). The incremental effect of C 48/80 treatment when 
combined with diprotin A may have resulted on the one hand from the induction of 
mast cell degranulation with C 48/80 and the release of several mediators of 
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inflammation including chemoattractant molecules (MCP-1, GM-CSF) and proteases. 
On the other hand, application of diprotin A enhanced the SDF-1α levels, which 
accelerated the recruitment of leukocytes including mast cells, which in turn provide 
growth factors and proteases for arteriogenesis. 
 
4.6. What is the relative contribution of mast cells and of leukocytes in arterial 
growth? 
The rate of blood flow recovery was significantly accelerated after the degranulation 
of mast cells was enhanced by the application of C 48/80 as well as after an 
enhancement of the recruitment of mast cells and of other leukocytes. Therefore, 
each of these mechanisms could have contributed in parallel to some extent to the 
final result, i.e. to the accelerated recirculation. Alternatively, the activation of one of 
these mechanisms (e.g. degranulation of mast cells) was a precondition for the 
activation of another mechanism (e.g. recruitment of leukocytes). To find out, a group 
of wild type mice was treated with a combination of diprotin A plus cromolyn. Thereby 
mast cells were stabilized (by applying cromolyn) and their recruitment remained 
ineffective whereas the recruitment of leukocytes was accelerated (by applying 
diprotin A). Interestingly, the significantly faster rate of blood flow recovery observed 
in diprotin A treated mice was absent in mice treated with a combination of diprotin A 
plus cromolyn (figure 13 E and F). We conclude that degranulation of mast cells and 
their release of growth factors and chemokines/cytokines provides a necessary 
environment for the recruitment of leukocytes. The small, non-significant increase in 
the rate of hindlimb reperfusion in cromolyn plus diprotin A treated versus cromolyn 
treated mice (figure 14D) might be explained by the relatively small number of 
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leukocytes that were recruited by diprotin A under the condition that mast cells were 
stabilized (see figure 20B). This result implies that diprotin A recruits leukocytes 
mainly indirectly via mast cells.   
 
4.7 Mast cell granula store a number of growth factors, cytokines and proteases   
Both, mast cells as well as leukocytes accelerate the rate of blood flow recovery. 
However, since mast cells are activated at an earlier stage to respond after the 
occlusion of an artery than leukocytes, our focus of interest had turned towards the 
content of mast cell granules. They contain growth factors (e.g. FGF-2 and PDGF-
BB), chemoattractant cytokines, chemokines (e.g. MCP-1, TNF-α, GM-CSF and 
interleukines) and essential proteases (i.e tryptase and chymase, which are essential 
for MMP activation) (Qu et al., 1998, Nakayama et al., 2006). Each of these 
compounds has been assumed in different studies to promote arteriogenesis (Wolf et 
al., 1998, Deindl et al., 2003, Hoefer et al., 2004). Of particular interest are MCP-1 
and TNF-α, because upon up-regulation they exert a strong effect on arteriogenesis. 
Both MCP-1 and its receptor CCR-2 have been demonstrated to be induced in 
arteriogenesis (Hoefer et al., 2004) and MCP-1 was associated with increased 
perivascular leukocyte recruitment in growing collateral arteries (Ito et al., 1997). 
When mast cell granules were cultured with endothelial cells, significant levels of 
MCP-1 were released and gene expression of MCP-1 mRNA levels were also 
increased in comparison to control values (Kinoshita et al., 2005).  
 
4.8. Mast cells up-regulate MCP-1 
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The level of MCP-1 mRNA in collaterals was up-regulated 12 hours after femoral 
artery ligation. With respect to the control mice, quantitative real time – polymerase 
chain reaction (qRT-PCR) exhibited a significant increase in MCP-1 mRNA levels in 
collaterals of mice treated with C 48/80 + diprotin A (figure 14 A). This result 
corresponds to the increase in protein levels of MCP-1 in the collaterals of the hind 
limb on the occluded side. However, plasma levels of MCP-1 were not significantly 
increased in mice treated with a combination of C 48/80 + diprotin A (Fig. 14C). The 
absence of such an increase could have resulted from a strong dilution of MCP-1  in 
the blood. Our results clearly show that mast cells up-regulate MCP-1 in growing 
collateral vessels and increase MCP-1 protein levels during arteriogenesis. Similar 
studies have shown that mast cells release the stored cytoplasmic MCP-1 following 
its activation as well as induce endothelial cell up-regulation and production of MCP-
1 (Kinoshita et al., 2005, Nakayama et al., 2006). These findings clearly demonstrate 
that the increased MCP-1 upregulation resulted from mast cell degranulation. As a 
consequence, MCP-1 recruits monocytes which leave the vessel, become 
macrophages with growth factors. The release of these growth factors promotes 
proliferation of endothelial and smooth muscle cells (Arras et al., 1998).  
4.9. Mast cells release TNF-α 
Another chemokine, that is released by mast cell granula is the tumor necrosis factor-
alpha (TNF-α) which  promotes leukocyte recruitment and represents an important 
mediator of inflammation (Bradley, 2008). Although, monocytes and macrophages 
contains TNF-α,  several studies revealed that mast cells are the major constituent of 
cytokines including TNF-α (Marone et al., 1995, Ribatti et al., 2001). Vascular 
endothelial cells respond to TNF-α by undergoing a number of pro-inflamatory 
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changes, which increase leukocyte adhesion and transendothelial migration (Munro 
et al., 1989). During arteriogenesis, TNF-α modulates collateral artery growth by 
activating the p55 receptor of endothelial cells (Hoefer et al., 2002). It has been 
reported in the same study that the perfusion of the distal hindlimb on the occluded 
side was impaired in TNFα-/- mice compared to the wild-type mice 7 days after 
femoral ligation.  
To find out whether mast cells are responsible for the release of TNF-α, one group of 
mice with a femoral artery ligation was treated with cromolyn, in order to inhibit mast 
cell degranulation, another group of mice with a femoral artery ligation was treated 
with saline (control with ligation) and a third group of mice without ligation was 
treated with saline as well (control without ligation). As a result, mice treated with 
cromolyn exhibited a reduced plasma level of TNF-α when compared to control with 
ligation (figure 15). These findings correlate with the results of an earlier study 
(Bissonnette et al., 1995), in which it was shown that sodium cromoglycate 
(cromolyn) inhibited the release of TNF-α from rat peritoneal mast cells.  
Upon stimulation with ionomycin mast cells release extracellular RNA (eRNA; Prof. P. 
Klaus, Giessen Germany, pers. communication) which in turn promotes the TNF-α 
converting enzyme (TACE) and TACE was found to induce a cleavage of membrane 
bound pro-TNF-α from monocytes (Fischer et al., 2013). In essence, the elevated 
plasma level of TNF-α during arteriogenesis is achieved by mast cells. Degranulation 
and release of cytoplasmatic TNF-α is one mechanism and induction of 
monocytes/macrophages to release TNF-α through the eRNA-TACE pathway is 
another mechanism.  
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4.10 Mast cells recruit leukocytes in the region of arteriogenesis 
MCP-1 and TNF-α are associated with increased perivascular leukocyte recruitment 
in growing collateral arteries (Randolph and Furie, 1995, Ito et al., 1997). In 
agreement with these results we detected significant leukocyte recruitment in the 
perivascular space of adductor muscle sections of the hindlimb on the occluded side 
of C 48/80 + diprotin A treated mice when we used CD45+, a leukocyte maker for 
staining. Conversely, significantly lower perivascular leukocyte recruitment than in C 
48/80 + diprotin A treated mice was seen after a treatment either with cromolyn or 
with a combination of cromolyn and diprotin A (figure 16). 
The increased leukocyte recruitment during arteriogenesis in the perivascular space 
of collaterals and hence adductor muscles were further investigated quantitatively 
using flow cytometry. 24 hours post ligation we found in the adductor muscles of 
mice treated with C 48/80 + diprotin A that different markers for subtypes of 
leukocytes revealed significantly increased numbers of macrophages (marker 
F4/80+) and neutrophils (marker Gr-1+ CD115-) in C 48/80 + diprotin A treated mice 
when compared to controls (figure 21A). 
In the blood of the same mice we found 24 hours after femoral ligation significantly 
increased levels of neutrophils (marker Gr-1+ CD115-) and T-lymphocytes (both CD4+ 
and CD8+ cells) in mice treated with a combination C 48/80 + diprotin A (figure 21 D). 
Furthermore, when we investigated leukocyte subpopulations in the m.adductors 3 
days after ligation, the numbers of macrophages (marker F4/80+) were significantly 
elevated in C 48/80 + diprotin A treated mice, whereas the increase in the numbers 
of neutrophils was not significant anymore in comparison to control values. When 
94 
 
blood was analysed 3 days after ligation, we found no differences in the leukocyte 
subpopulations in C 48/80 + diprotin A treated mice versus control mice (figure 21 J).   
As described previously, an increase in the number of perivascular leukocytes is an 
essential prerequisite for vessel growth during arteriogenesis (Schaper et al., 1976). 
Our results obtained in C 48/80 + diprotin A treated mice clearly demonstrate an 
increased number of leukocytes in the perivascular space of growing collateral 
arteries as well as in the blood. From the presence of increased numbers of 
leukocytes in adductor muscles and in the blood of mice treated with a combination 
of C 48/80 plus diprotin A we conclude that the activation of mast cells and their 
release of MCP-1 and TNF-α recruit leukocytes in the region of arteriogenesis. 
4.11. Mast cells promote vascular remodelling   
The growth of pre-existing arterial collaterals involves a degradation of extracellular 
matrix by specialized enzymes, called matrix metalloproteinases (MMP). This 
process of tissue reshaping has become the centre of attention in relation to 
physiological and pathological vascular remodelling. MMP are a family of enzymes 
that proteolytically degrade various components of the extracellular matrix proteins. 
They play a central role in morphogenesis, wound healing, and tissue repair and 
remodelling (Newby, 2005). Brower et al. (2002) reported that after the formation of 
an atrio-ventricular fistula there was a marked elevation in cardiac MMP activity, 
which corresponded with significant collagen degradation and a rapid increase in the 
number of cardiac mast cells.  
Baram et al (2001) showed that MMP-9 is released by mast cells and when cultured 
mast cells were treated with phorbol 12-myristate 13-acetate they expressed MMP-9 
mRNA (Kanbe et al., 1999). In our experiments, a significant increase in the MMP 
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activity with respect to control mice was present in mice which received a combined 
treatment with substances that recruit mast cells (diprotin A) and that in addition 
degranulate them (C 48/80). Conversely, the number of degranulated mast cells and 
the level of MMP activity decreased after the application of cromolyn.  
 
The observed significant increase in the MMP activity after a treatment with C48/80 + 
diprotin A  (figure 15) might have resulted from a release of MMP from activated mast 
cells or from the activation of pro-MMP to active MMP by proteases such as tryptase 
and chymase which are known to be released from activated mast cells (Baram et 
al., 2001). The importance of MMP in angiogenesis is mostly seen in the degradation 
of the vascular basement membrane and in the remodelling of the extracellular 
matrix which allows leukocytes to migrate and to invade the surrounding tissue 
(Rundhaug, 2005). Furthermore, mast cells are associated with the increased 
activation of MMP in up-regulating angiogenesis in squamous epithelial 
carcinogenesis (Coussens et al., 1999). In addition, the relevance of MMP-2 and 9 
has also been described in arteriogenesis (Wolf et al., 1998, Cai et al., 2004). 
Although mast cell enzymes have been implicated in being involved in the MMP 
activation cascade by several in vitro and in vivo studies (Brower et al., 2002) our 
study is the first one to demonstrate that mast cells are capable of triggering 
significant MMP activation in growing collateral arteries. This result is novel in so far 
as mast cells are identified as potential regulators for the mechanism of vessel 
remodelling and luminal growth as shown by the increased size of collateral arteries 
7 days after femoral ligation in the group of mice that received a combination of  C 
48/80 + diprotin A (figure 22 A).   
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4.12 .  Mast cells promote the proliferation of endothelial and smooth muscle cells 
 
The hallmark of vessel growth is vascular cell proliferation (Pasyk et al., 1982) which 
follows vascular remodelling. After a treatment of mice with C 48/80 + diprotin A we 
observed an increased MMP activity, which is an important factor for remodelling, but 
this treatment resulted in an increased proliferation of vascular cells as well. In the 
blood of C 48/80 + diprotin A treated mice we found an elevation in the level of the 
growth factor PDGF-BB. This growth factor as well as FGF-2 was shown to be 
present in mast cells in the perivascular space of collaterals (Max-Planck-Institute for 
Heart and Lung Research, Bad Nauheim, Germany; pers. communication). In 
addition, it has been shown previously in rats and rabbits that combined treatment 
with FGF-2 and PDGF-BB strongly promotes arteriogenesis (Cao et al., 2003). In 
order to inhibit the effect of diprotin A, we treated another group of mice with 
cromolyn + diprotin A, which resulted in fewer proliferating vascular cells than in C 
48/80 + diprotin A treated mice (figure 17 A-D). Furthermore, a research group in 
Giessen has shown that in vitro degranulation of mast cells with ionomycin induces a 
proliferation of cultured endothelial cells (pers. communication). These in vitro result 
support our conclusion that mast cell derived factors promote vascular cell 
proliferation. Our results demonstrate for the first time a direct involvement of mast 
cells in the remodelling and in the proliferation of endothelial and smooth muscle 
cells during arteriogenesis. These two findings have the power to open a new 
concept in the chapter of arteriogenesis.  
 
4.13. Accelerated perfusion after femoral artery ligation reduces muscle damage 
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The extent of tissue damage in distal hindlimb muscles on the occluded side is 
expected to dependent on the time course of the recovery of an efficient perfusion 
and hence on the progress of arteriogenesis. The degree of skeletal muscle damage 
will directly correlate with the severity and duration of ischemia and inversely with 
the extent of collateral vascular growth and the resulting reperfusion (Scholz et al., 
2002). The same study compared the cell damage in the gastrocnemius muscle 
tissue of two different strains of mice (Balb/Cs and C57Bl/6).  Balb/Cs mice had a 
50% poorer perfusion recovery in comparison to C57BL/6 mice and their poorer 
perfusion recovery was associated with an increased angiogenesis and muscle 
tissue damage.  
An efficient reperfusion requires an enlargement of the diameters of growing 
collateral arteries. Therefore, we analysed histological sections of distal adductor 
muscle from the occluded side of C 48/80 + diprotin A treated mice and compared 
them with sections from the controls. Already 3 days post ligation an increase in the 
luminal diameter of collateral vessels by a factor of 1.3 was observed. A further 
increase by a factor of 1.7 was seen 7 days after ligation with respect to control 
values (figure 21). This collateral luminal expansion correlates to our laser Doppler 
perfusion imaging data, which showed a faster recovery of the blood flow in the 
distal hindlimb after femoral artery ligation in combined C 48/80 + diprotin A treated 
mice in comparison to controls.  
In the distal lower limb a significantly smaller area of damaged calf muscle tissue 
was revealed by histological analysis in mice treated with a combination of C 48/80 
+ diprotin A with respect to control mice. The preserved calf muscles tissue seen in 
the histological sections might have resulted from an earlier increase in blood flow 
recirculation in mice with a combined C 48/80 + diprotin A treatment as shown by 
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laser Doppler imaging (LDI;  figure 13D and figure 22 M). In this group of mice with a 
combined C 48/80 + diprotin A treatment the muscle tissue looked very similar to 
that on the sham operated side. Correspondingly, the ratio of capillary per muscle 
fibre in mice with a combined C 48/80 + diprotin A treatment was significantly 
reduced with respect to control mice (figure 22). This implies that angiogenesis was 
also reduced in mice with a combined C 48/80 + diprotin A treatment.  
In reaction to ischemic injury, leukocyte infiltration is increased (Ysebaert et al., 
2000). Given that the calf muscle on the occluded side of treated mice was so well 
preserved, we expected that fewer leukocytes had infiltrated the gastrocnemius 
muscle of treated mice. Therefore, we assessed the number of leukocytes in this 
muscle with the help of CD45 antibody staining. Consistent with our expectation we 
found significantly fewer numbers of leukocytes in mice treated with a combination of 
C 48/80 + diprotin A than in control mice.  
 
4.14. Reactive oxygen species activate mast cell degranulation in response to 
arterial occlusion 
In this study we have clearly shown that mast cells are located in the perivascular 
space of quiescent collateral arteries (figure 10 A). Following femoral artery ligation, 
mast cell releases their granular content by a process known as degranulation 
(figure 10 B). However, so far the mechanism of mast cell degranulation is not 
understood. In a series of experiments, we attempted to find the likely cause for 
mast cell degranulation during untreated arteriogenesis. Given the close proximity 
between mast cells, nerve fibres and accompanying blood vessels, the release of 
substance P from nerve endings could be responsible for the degranulation. 
Substance P has been reported in several studies as a potent mast cell degranulator 
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(Suzuki et al., 1995, Saban et al., 2002). However, after we had blocked the release 
of substance P in a group of mice the time course of blood flow recovery in this 
group was not different from the time course of recovery in control mice.  
 
Reactive oxygen species (ROS) are produced in cells as normal product of cellular 
metabolism. The cellular level of these products is regulated by specific enzymes 
e.g. dismutase and catalase to prevent deleterious effects (Stadtman, 1992). 
Reactive oxygen species (ROS) have been implicated in inducing mast cell 
activation (McCauley et al., 2005, Swindle and Metcalfe, 2007). Since neutrophils 
are the first cells to promote inflammation and since they release oxygen free 
radicals (Tidball, 1995), we propose that neutrophils might be involved in mast cell 
degranulation through the production of ROS. When we applied a substance which 
depletes neutrophils (Ly6G/1A8) we found a significant reduction in the rate of 
recovery of blood flow at day 7. A histological analysis documented a decreased 
percentage of mast cell degranulation 24 hours after femoral artery ligation. To 
further investigate a possible role of reactive oxygen species in mast cell 
degranulation during arteriogenesis, we stained sections of adductor muscles from 
Nox-2-/- mice and found a reduced percentage of degranulated mast cells around the 
collaterals 24 hour after femoral artery ligation. Next, we treated mice with N-
acetylcysteine or apocynin to reduce the level of ROS. In this experiment, we 
investigated the degranulation of mast cells 24 hour after femoral artery ligation. In 
both groups of mice, the percentages of degranulated mast cells were significantly 
decreased when compared to control values. This suggests that ROS derived from 
extravasated neutrophils plays a role in mast cell degranulation during 
arteriogenesis. A crucial role of platelets in arteriogenesis is further emphasized by 
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the fact that the percentage of mast cell degranulation in GPIbα-/- mice was 
decreased 3 days after femoral artery occlusion when compared with wild type mice. 
In essence we suggest, neutrophils interact with platelets through the platelets 
receptor GPIbα (Zarbock et al., 2007, von Bruhl et al., 2012) with the result that 
urokinase-type plasminogen activator (UPA) promote more neutrophils to 
accumulate in the perivascular space (Reichel et al., 2011) and finally ROS release 
(figure 24).  
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Figure 24. A proposed model showing mechanism of mast cell degranulation and 
action 
After femoral artery ligation neutrophils and platelets interact in collateral arteries. 
This interaction results in uPA dependent extravasation of neutrophils and in a 
release of neutrophil derived ROS from Nox 2. Next, ROS degranulate mast cells. 
Mast cells release factors which promote vascular remodelling (MMP), vascular cell 
proliferation (FGF-2 and PDGF-BB) and leukocyte recruitment (TNF-a, MCP-1). 
Finally resulting in enhanced collateral artery growth. 
 
4.15.  Mast cell activation – a therapeutic target for patients? 
This study has demonstrated that the recovery of perfusion after arterial occlusion 
can be accelerated by enhanced mast cell recruitment and degranulation. The 
pharmacological treatment of mice with diprotin A and with the compound 48/80 
encouraged the enlargement of collateral arteries, improved the blood supply of 
distal muscles and reduced the ischemia related damage of distal muscle tissue 
after the occlusion of a major artery. These beneficial consequences of mast cell 
recruitment and degranulation could also be exploited clinically by an application of 
diprotin A and C 48/80 in patients with vascular occlusive diseases. In fact, drugs 
like sitagliptin (The dipeptidylpeptidase–IV inhibitor) are used in the clinic to treat 
patients with type-2 diabetes mellitus (Eurich et al., 2013), this drug also can be 
employed to mobilize leukocytes to the region of collateral artery growth. Since there 
is no known clinical means of inducing mast cell degranulation, this is left as an 
important area to research. 
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5. SUMMARY  
In a mouse model, we investigated the functional role of mast cells for the growth of 
pre-existing arterial collaterals into functional bypasses after the ligature of the 
femoral artery on one side. A major finding consisted in the discovery of a regionally 
restricted mast cell degranulation in the vicinity of growing collaterals. Such a mast 
cell response was neither present in ischemic muscles of the lower limb nor on the 
sham-operated side. The observed degranulation stimulated our search for functional 
contributions of mast cells in arteriogenesis.  
The functional consequence of mast cell degranulation for the recovery of the blood 
flow distal to the ligature was quantified with the help of laser Doppler imaging. The 
recovery of blood flow in the distal hindlimb was accelerated both by an enhanced 
degranulation of mast cells (after the application of C 48/80) as well as by an 
enhanced recruitment of mast cells (after the application of diprotin A). A combined 
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application of C 48/80 plus diprotin A synergistically accelerated the recovery of distal 
blood flow. Stabilization of mast cells (after the application of cromolyn) reduced the 
number of degranulated mast cells and slowed down the speed of recovery of distal 
blood flow. 
Mast cell degranulation up regulated the monocyte chemotactic protein (MCP)-1 and 
increased the release of TNF-α.  Both cytokines are essential for leukocyte 
recruitment as shown by CD45+ antibody staining. Hence, degranulation of mast cells 
mediates the activation of leukocytes, which play an important role in arteriogenesis. 
In addition, activated mast cells supply FGF-2 and PDGF-BB, which are important for 
endothelial and smooth muscle cell proliferation. Mice treated with a combination of 
C 48/80 + diprotin A exhibited an increased vascular cell proliferation. Hence, we 
conclude from these results that C 48/80 + diprotin A degranulate mast cells, which 
release growth factors like FGF-2 and PDGF-BB and thereby enhance vascular cell 
proliferation. As a consequence, the diameters of collateral arteries increase and 
vascular blood flow improves.  
The growth of collateral arteries is known to be accompanied by an activation of 
matrix metalloproteinases (MMP). These enzymes are responsible for vascular 
remodelling and the degradation of the extracellular matrix. In our experiments, the 
MMP activity was significantly increased with respect to control mice whenever mast 
cell recruitment and mast cell degranulation were both enhanced by the combined 
application of C 48/80 plus diprotin A.  
The accelerated rate of arteriogenesis in the upper hind limb due to an enhanced 
degranulation of mast cells resulted in a reduced amount of tissue damage in the 
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gastrocnemius muscle. This reduced tissue damage was accompanied by less 
capillary proliferation and by fewer leukocytes infiltrating the gastrocnemius muscle.  
Given the important role of mast cells in arteriogenesis, we finally investigated how 
mast cell degranulation is accomplished during the untreated growth of collateral 
arteries. As a result, our study showed an involvement of platelets and neutrophils. 
The latter release reactive oxygen species and thereby activate mast cells. Taken 
together these data demonstrate that mast cells are major players in arteriogenesis. 
Their degranulation accelerates the enlargement of collateral arteries and as a 
consequence reduces ischemic damage of the distal tissues.  
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